<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of transgender and gender-diverse children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of transgender and gender-diverse children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of transgender and gender-diverse children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Johanna Olson-Kennedy, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michelle Forcier, MD, MPH</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Brent, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mitchell E Geffner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Diane Blake, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H25477371"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Children generally are assigned a gender at birth based upon genital anatomy or chromosomes. For most children, gender assignment correlates with gender identity, which is the innate sense of self as male, female, a blend of both, or neither. However, some children have a gender identity that is not congruent with their assigned gender at birth. These children are described as transgender or gender-diverse (TGD) youth  (<a class="graphic graphic_table graphicRef86993" href="/d/graphic/86993.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Terminology'</a>.)</p><p>This topic will provide an overview of the management of gender diversity in children and adolescents. Gender development and the clinical presentation of gender diversity in children and adolescents are discussed separately. (See  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Referral'</a>.)</p><p class="headingAnchor" id="H231831"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Evidence to guide the management of gender diversity in children and adolescents has increased with the increasing numbers of multidisciplinary centers providing treatment for transgender or gender-diverse (TGD) youth [<a href="#rid1">1-4</a>]. This information supplements the experience from case series of adults who underwent gender-affirming surgery.</p><p>In the absence of a clear understanding of the etiology of gender diversity, a variety of views influence the management approach and may be applied according to the individual patient's needs and goals. Patient-centered approaches to treating TGD children and adolescents have been outlined by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpublications.aap.org%2Fpediatrics%2Farticle%2F142%2F4%2Fe20182162%2F37381%2FEnsuring-Comprehensive-Care-and-Support-for%3Fautologincheck%3Dredirected&amp;token=lznKj4VVtyvptCYev%2FHiN7RtlAjYevHtDjmyefJjFKlWqJLSCWhYPrpkoy3j3R7YYURNjH2RWTyeoSZRnTM98EO9A7azqqE%2Fu3fp5nm2K%2BJvf1BCyos2nrJ0616Bxvyemqp1WBjt3x5%2FIuIv3ggSmK6BNY01vi%2BBv%2B3ax82eJNc%3D&amp;TOPIC_ID=86771" target="_blank">American Academy of Pediatrics</a> [<a href="#rid5">5</a>], <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fprevention.ucsf.edu%2Ftranshealth&amp;token=dy475w9dGpPgAW4z5kgWDaM1vpm7jLuMXoGjeAX7c%2B2Nar4myWfy2TQ6pFgN4Qo%2B&amp;TOPIC_ID=86771" target="_blank">University of California, San Francisco Center of Excellence for Transgender Care</a> [<a href="#rid6">6,7</a>], the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.endocrine.org%2Fclinical-practice-guidelines&amp;token=Le2c4RlMYbLQVHkeMqrseO5fsxy712Dl2SKcFtrAKFiUeys0ioH5d90mKdRi40e93BScIuG%2Fc%2FRHy49qT0ph9g%3D%3D&amp;TOPIC_ID=86771" target="_blank">Endocrine Society</a> [<a href="#rid8">8</a>], the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aacap.org%2F%2F&amp;token=IQxLzDq4doJGUgaZgeIY0wbtxngImOQl9clEMMKa5oA%3D&amp;TOPIC_ID=86771" target="_blank">American Academy of Child and Adolescent Psychiatry</a> [<a href="#rid9">9</a>], and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.wpath.org%2F&amp;token=OqHbRR0lt%2FUEOwSsKCcy75BvTLrFQHvIsOThK%2BOQWn4%3D&amp;TOPIC_ID=86771" target="_blank">World Professional Association for Transgender Health</a> [<a href="#rid10">10</a>]. Our approach is generally consistent with the recommendations in these guidelines. (See <a class="local">'Society guideline links'</a> below.)</p><p>The information provided in this topic review is intended to allow primary care providers to educate and support patients and families of TGD youth and to coordinate care, provide referrals, provide additional psychosocial support from the medical home, and monitor patients receiving care from specialists (eg, monitoring laboratory work, drug side effects, drug-drug interactions).</p><p class="headingAnchor" id="H231838"><span class="h1">GUIDING PRINCIPLES</span><span class="headingEndMark"> — </span>Several principles guide the treatment of transgender or gender-diverse (TGD) youth; these include [<a href="#rid3">3,9,11-15</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The safety and well-being of the youth and their family members is foremost. Family acceptance and other affirming environments that create space for youth to express and grow into their authentic self are critical for healthy development [<a href="#rid16">16-18</a>]. Other treatment decisions must consider the potential for decreased sense of self-worth, depression, self-harm, suicidality, verbal victimization, physical victimization, etc. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Care for TGD youth is determined according to the individual's gender development, needs, and goals. Given the spectrum and fluidity of gender identity, it is important for health care providers to elicit and understand the specific needs of individual patients [<a href="#rid19">19</a>]. The degree and type of mental health and medical support and interventions may vary. Not all TGD youth desire phenotypic transition, hormones, or surgeries.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinicians who are neither comfortable nor willing to become sufficiently knowledgeable to treat TGD patients should refer them to more experienced colleagues.</p><p></p><p class="bulletIndent1">Given that TGD persons are increasingly visible and continue to seek medical and psychosocial resources, providers have increasing responsibility to be inclusive and to know about issues relevant to TGD patients. (See  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Epidemiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the United States, clinicians should be aware of transgender care-related legislation in their state. Some states have legislative bans on gender-affirming care that may result in penalties for clinicians and/or caregivers [<a href="#rid20">20</a>].</p><p></p><p class="headingAnchor" id="H25477604"><span class="h1">TYPES OF INTERVENTIONS</span></p><p class="headingAnchor" id="H83439611"><span class="h2">Mental health interventions</span></p><p class="headingAnchor" id="H967321736"><span class="h3">Mental health approaches</span><span class="headingEndMark"> — </span>There are several mental health approaches to support transgender or gender-diverse (TGD) children and adolescents explore their gender identity and find a gender role that is comfortable [<a href="#rid10">10,21</a>]. Treatment options may be influenced by family expectations, cultural differences, opinions of health professionals, insurance coverage, and availability of services.</p><p>The specific approach for a given child or adolescent is individualized. The process may or may not involve recommendations for a change in gender expression or body modification; what helps to alleviate gender dysphoria in one person may differ from what helps to alleviate it in another.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred approach</strong> – Affirming approaches are preferred; they are recommended by many professional organizations. (See <a class="local">'Society guideline links'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Affirming</strong> – Affirming approaches focus on gender identity/body congruence and actively promote exploration of gender development and self-definition within a safe setting [<a href="#rid5">5,11,22,23</a>].</p><p></p><p class="bulletIndent2">A fundamental concept of this approach is that gender diversity is not a mental illness. It is inappropriate to pathologize the child or adolescent's behaviors or to assign a diagnosis. With the help of affirming psychotherapy, some individuals can integrate their gender-diverse feelings into their birth-designated gender; others may be able to alleviate their gender dysphoria through changes in gender role and expression [<a href="#rid10">10,24</a>]. (See <a class="local">'Social transition'</a> below.)</p><p></p><p class="bulletIndent2">The authors of this topic review support affirming approaches for TGD youth – from medical and mental health professionals, as well as parents/caregivers. The growing medical evidence supports careful listening, thoughtful discussions, and patient-centered approaches to gender exploration.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approaches that are not recommended </strong>– Approaches that are not recommended and potentially harmful include wait-and-see approaches, redirection, and reparative therapy [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Wait-and-see</strong> – The wait-and-see approach (also called watchful waiting) involves waiting to see if the child's gender identity will change as the child gets older [<a href="#rid11">11</a>]. Caregivers who take this approach may allow different-gender play and clothing within the home or support both masculine and feminine activities as the child explores their interests in other social settings.</p><p></p><p class="bulletIndent2">The wait-and-see approach assumes that gender is binary and becomes fixed at a certain age; it pathologizes gender diversity and fluidity [<a href="#rid5">5</a>]. It is distinguished from following the child's lead, an affirming approach that allows the child to present in the gender role that feels correct and moves at a pace determined by the child. (See <a class="local">'General suggestions'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Redirection</strong> – Some mental health therapists encourage caregivers to use positive reinforcement to try to "redirect" children toward behavior that is more typical of their birth-designated sex or less gender specific. The goal of redirection is to eliminate gender-diverse desires and expressions over time [<a href="#rid25">25</a>]. This approach is not recommended because negative reinforcement (eg, shaming the child for gender-diverse expression) has substantial negative mental and social health consequences.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Reparative therapy</strong> – Reparative therapy (also called conversion therapy) claims to be able to "cure" a transgender identity. It is still practiced in certain religious and conservative communities. This approach was initially used in the 1970s [<a href="#rid26">26,27</a>]. Reparative therapy is considered unhelpful and potentially harmful by most professional organizations, including the American Academy of Child and Adolescent Psychiatry, the American Academy of Pediatrics, the World Professional Association for Transgender Health, the Society for Adolescent Health and Medicine, and the Substance Abuse and Mental Health Services Administration [<a href="#rid5">5,10,28-34</a>]. In the United States, several states, counties, and cities ban reparative therapy. The Movement Advancement Project provides a <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.lgbtmap.org%2Fequality-maps%2Fconversion_therapy&amp;token=%2FIWsE0N4PYYTvlNDBVg8QA4ArGIGmGG5b0p2unEP7jlHv2f1H7uya1iJ2hqcgHsAjeBYPxl2fKYWmI%2F0GucakA%3D%3D&amp;TOPIC_ID=86771" target="_blank">map</a> of localities that ban reparative therapy.</p><p></p><p class="headingAnchor" id="H4186224553"><span class="h3">Indications for mental health referral</span><span class="headingEndMark"> — </span>Referral to a mental health provider may be warranted for [<a href="#rid23">23,35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prepubertal children with evidence of gender dysphoria (eg, aversion to aspects of their body associated with sex; wish to live as opposite sex); coexisting anxiety, depression, or suicidality; or serious interpersonal conflicts with peers (eg, bullying) or caregivers. Bullying that occurs at school should also be addressed by school personnel.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Any youth who wants additional support and resources to explore transgender and/or nonbinary gender identities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Peripubertal and postpubertal youth who are not gender dysphoric but seeking additional psychosocial support and planning for affirmation  (<a class="graphic graphic_table graphicRef87390" href="/d/graphic/87390.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Caregivers of TGD children and adolescents who are uncomfortable or rejecting of their child's identity and behaviors or are simply seeking a space to express their concerns and feelings about their TGD child.</p><p></p><p class="bulletIndent1">(See  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Referral'</a>.)</p><p></p><p class="headingAnchor" id="H83439674"><span class="h2">Phenotypic interventions</span></p><p class="headingAnchor" id="H65066665"><span class="h3">Social transition</span><span class="headingEndMark"> — </span>"Social transition" is a reversible intervention in which the youth lives partially or completely in their asserted gender role by adapting hairstyle, clothing, pronouns, and possibly assuming a new name. Social transition also may include wearing make-up or clothing modification to hide the effects of puberty (eg, wearing a binder to hide breast development, tucking the penis and testicles so they are not visible, wearing protheses or packers to simulate body parts), and using devices that permit urination while standing (for transmasculine individuals).</p><p>Patients and families may decide to have a "trial run" to allow the child to see how it feels and the parents/caregivers and health care providers to see how the child responds. Patients and families decide in advance the extent of the changes (eg, clothing, pronouns, name), whether and to whom to disclose, and how to handle common potential challenges (eg, bathrooms, locker rooms, sleepovers).</p><p>Decisions regarding social transition are individualized after considering the potential benefits (eg, alleviation of psychological distress) and the risks (eg, safety concerns) [<a href="#rid11">11</a>]. Studies of the effects of social transition on future physical and mental health are ongoing. Longitudinal studies suggest that symptoms of anxiety and depression in TGD children improve with social and physical transition [<a href="#rid12">12,36-39</a>] and that, among socially affirmed children, caregiver- and child-reported rates of depression are similar to rates in cisgender (gender identity is aligned with gender assigned at birth) age- and gender-matched controls, cisgender sibling controls, and typical rates, while rates of anxiety are only slightly higher [<a href="#rid16">16,17,40</a>]. In these studies, the levels of depression and anxiety symptoms were substantially lower than those reported in previous studies in children with gender diversity who were not socially transitioned [<a href="#rid41">41-44</a>].</p><p>The safety of the child or adolescent and the likelihood of acceptance in the community are important considerations in making decisions about social transition and planning. Providers can help youth and families make positive and successful social transition plans by:</p><p class="bulletIndent1"><span class="glyph">●</span>Helping them plan for disclosure to family, friends, and social contacts</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Educating staff and students within the school system</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Creating plans for safety, responses to bullying, and other social biases</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing medical documentation for name change, gender change, and other official documents; the , among others, provides information about what to include in the medical documentation</p><p></p><p>These suggestions are discussed separately. (See  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Role of the medical provider'</a>.)</p><p>Different communities approach gender diversity differently. Some are supportive; in others, a fully disclosed transition of gender expression may be hazardous for the youth's well-being. Caregiver assessment of the potential for danger may be inaccurate. For caregivers who are unsure or have difficulty accepting their TGD child, safety concerns may be used to delay social transition and medical affirmation options. </p><p>Families can contact a number of local or national social and advocacy agencies to assist in making a safety assessment or in facilitating social transition in school and other settings. Such organizations work with schools, teachers, and students to assist in developing plans for use of bathroom and locker room accommodations, registration questions, and overall education about gender-related issues. The involvement of these agencies allows caregivers to focus on caring for their TGD child rather than bringing about social change. (See <a class="local">'Resources'</a> below.)</p><p class="headingAnchor" id="H65066672"><span class="h3">Hormonal interventions</span><span class="headingEndMark"> — </span>Hormonal interventions (eg, suppression of endogenous puberty and/or initiation of gender-affirming hormones to alter secondary sexual characteristics) may be beneficial for transgender or nonbinary adolescents with strong feelings of gender dysphoria after the onset of puberty [<a href="#rid1">1,45</a>]. These interventions are discussed in detail below. (See <a class="local">'Overview of hormonal interventions for adolescents'</a> below.)</p><p class="headingAnchor" id="H191437845"><span class="h3">Surgical interventions</span><span class="headingEndMark"> — </span>Many youth and caregivers have questions about gender-affirming surgical interventions for gender affirmation. It is important to respond to these questions, acknowledge the possibility of surgical intervention in the future, and to make referrals as necessary when youth reach a stage when surgery may be appropriate. However, for children and early adolescents, we redirect the focus to social and medical interventions. Early identification and interventions that affirm TGD children may help to avoid future gender-affirming surgeries. While most genital surgeries are performed after individuals reach the age of majority (the definition of which varies geographically), chest dysphoria (distress about a female chest contour) is debilitating for many transmasculine youth, and chest reconstruction during adolescence is common [<a href="#rid46">46</a>]. (See <a class="local">'Surgical interventions'</a> below.)</p><p class="headingAnchor" id="H25477379"><span class="h1">APPROACH IN PREPUBERTAL CHILDREN</span></p><p class="headingAnchor" id="H82396173"><span class="h2">General suggestions</span><span class="headingEndMark"> — </span>The trajectory of gender diversity in prepubertal children is unpredictable for some children [<a href="#rid47">47-49</a>]. Others have consistent, persistent, and insistent gender-diverse identities or expression. In either case, children who live as their authentic selves and who feel safe, loved, and accepted in their homes by their caregivers have better health outcomes [<a href="#rid16">16</a>].</p><p>Thus, it is reasonable for the primary care provider to offer education, support, and referrals as indicated [<a href="#rid2">2,12,50,51</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Educate parents/caregivers about the possible gender and psychosexual trajectories.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Encourage a wide range of interests, activities, and friend groups.</p><p></p><p class="bulletIndent1">Work with leaders in youth settings to decrease the focus of arbitrarily gendered activities or attributes (eg, basketball is for boys, dance is for girls; boys are brave and girls are sensitive).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Follow the child's lead with respect to gender expression but set limits as necessary for safety; children who have severe gender dysphoria usually are skilled at articulating their need to present in the gender role that feels correct for them.</p><p></p><p class="bulletIndent1">Some prepubertal children who exhibit consistent, persistent, and insistent gender diversity or gender and body dysphoria pursue a social transition; prepubertal children who are experimenting with gender play or have less intense gender dysphoria are less likely to endorse transgender or other gender-diverse identities in adolescence and adulthood; much of a child's ability to express gender authentically depends upon the caregivers' and family's openness to a broader gender spectrum and expression [<a href="#rid52">52</a>]. (See <a class="local">'Social affirmation and transition'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Given the spectrum of gender diversity, it is important to support youth with less traditional gender identities in their gender evolution and to tolerate ambivalence about gender (eg, transition, affirmation, goals) rather than using it as a reason to hinder exploration or affirmation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Protect the child against negative reactions from others.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Address concomitant emotional, behavioral, or family problems that may (or may not) have an impact on the child's feeling of acceptance in a family or on their gender dysphoria. Encourage caregivers to seek mental health and other supports for themselves so that they may privately process their feelings and responses to their child.</p><p></p><p>Additional suggestions for education and support are provided separately. (See  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Education and support'</a>.)</p><p class="headingAnchor" id="H180361577"><span class="h2">Social affirmation and transition</span><span class="headingEndMark"> — </span>Most medical and mental health professionals agree that the approach to social affirmation in prepubertal children should be individualized; that the caregivers' role is to support what is best for the child [<a href="#rid50">50,53</a>]; and that all children are more likely to have a healthy self-image, self-esteem, and general well-being when their authentic identity is recognized, supported, and loved [<a href="#rid51">51</a>]. It is not uncommon for providers to meet families with socially transitioned prepubertal children who made the decision without medical input [<a href="#rid23">23</a>]. For these youth and families, medical and mental health professionals can provide additional information and resources to support and create a plan for upcoming puberty. (See <a class="local">'Resources'</a> below.)</p><p>Although evidence regarding long-term outcomes is limited [<a href="#rid10">10</a>], clinical observation suggests that social transition and affirmation among children age 6 to 14 years decreases anxiety and depression [<a href="#rid17">17</a>]. In the experience of the authors of this topic review, social transition and affirmation are beneficial for many prepubertal children with persistent, strong diverse gender identity who have difficulty functioning adequately in their familial, social, and educational domains without being allowed to express their authentic gender identity. The potential for negative response and safety concerns (including bullying, harassment, rejection, isolation, and violence) must be balanced with the child's becoming incapacitated by living inauthentically. (See <a class="local">'Social transition'</a> above.)</p><p>Retransition after social transition appears to be uncommon. In a longitudinal study, five years after social transition, 2.5 percent of 317 initially transgender youth were living as cisgender youth and 3.5 percent were living as nonbinary youth; 4 participants transitioned to nonbinary or cisgender and then back to transgender [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H25477701"><span class="h1">APPROACH IN PUBERTAL CHILDREN AND ADOLESCENTS</span><span class="headingEndMark"> — </span>Gender dysphoria that persists through the onset of puberty or emerges and/or increases at the onset of puberty is unlikely to subside [<a href="#rid1">1,2,55</a>].</p><p class="headingAnchor" id="H214554643"><span class="h2">Care setting</span><span class="headingEndMark"> — </span>Supportive and affirming care for adolescents can be provided in a variety of settings. Many youth benefit from multidisciplinary gender specialty programs that include medical, mental health, and social work services [<a href="#rid8">8,10,11</a>]. However, access to multidisciplinary centers may be limited. As more providers become informed, trained, and adept at working with gender-diverse youth, youth and families may have additional options for care within primary care and community mental health venues [<a href="#rid23">23</a>].</p><p>Telehealth presents another opportunity for expanding access to care. Patients who live a long distance from gender-affirming hormone (GAH) providers, as well as teens without access to transportation, may benefit from this service. In one study, more than one-half of the teens reported that they would be likely or very likely to use telehealth for future confidential care [<a href="#rid56">56</a>]. Yet, many participants also expressed concern about finding a private space to speak confidentially with the provider without being overheard by family members.</p><p class="headingAnchor" id="H514590732"><span class="h2">Individualized care</span><span class="headingEndMark"> — </span>Given the spectrum and fluidity of gender identity and embodiment goals the management needs differ from adolescent to adolescent. Adolescents may change their transition goals and requests for treatment over time according to personal desire and circumstance. Some gender-diverse youth do not desire a phenotypic transition and are content with their endogenous hormones. They may identify as transgender, or they may identify as something different (eg, "gender fluid," "gender creative"). A comprehensive biopsychosocial assessment enables providers to understand the individual needs of each transgender or gender-diverse (TGD) youth within the context of human development and diversity [<a href="#rid10">10</a>]. The assessment includes pubertal progress, gender identity development and consolidation, social development and support, evaluation for possible co-occurring mental health or developmental concerns, capacity for decision-making, and readiness of the youth and caregivers for medical interventions. (See <a class="local">'Youth with a nonbinary gender identity'</a> below and  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Terminology'</a>.)</p><p class="headingAnchor" id="H1804809516"><span class="h2">Youth with a binary gender identity</span><span class="headingEndMark"> — </span>To allow time for the adolescent to develop the maturity necessary to make a thorough and informed decision about permanent physical changes, some youth may progress from nonmedical reversible adaptations that express their gender identity, such as changes in hair, clothing, name, and pronoun to reversible medical interventions (eg, pubertal suppression). Others may want more information and opt for partially reversible interventions (eg, GAH) or irreversible interventions (eg, surgical).</p><p>However, not all affirmative care starts with social transition. Some youth are uncomfortable making changes in their gender presentation before undergoing hormonal intervention because of fear of harassment, bullying, and physical violence. It is important for providers to honor the needs of each youth and to understand the strategic decision-making that allows the youth to feel most comfortable and safe. Youth who make the decision to socially transition after starting hormones should not have their care delayed. (See <a class="local">'Guiding principles'</a> above and <a class="local">'Social transition'</a> above and <a class="local">'Overview of hormonal interventions for adolescents'</a> below.)</p><p class="headingAnchor" id="H10433361"><span class="h2">Youth with a nonbinary gender identity</span><span class="headingEndMark"> — </span>There are increasing numbers of youth presenting for gender services who endorse a gender identity that is neither male nor female, and do not conform to expected social standards but are somewhere in between or other. These youth may identify as "agender," "bigender," "gender fluid," "gender queer," "gender blender," or something else entirely. Some published articles suggest possible medical interventions for those with nonbinary gender identities, including short-term use of GAH, lower dosing strategies, or the use of less conventional hormones such as nandrolone or selective estrogen receptor modulators [<a href="#rid57">57,58</a>]. Medical treatment for nonbinary individuals highlights the importance of centering the embodiment goals of all TGD patients.</p><p>Clinicians who see large numbers of TGD youth report an increase in patients who are interested only in male chest reconstruction or <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> suppression. There is increasing interest in adapting gender care for gender-diverse youth who may not start or may not continue with <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> or testosterone [<a href="#rid59">59</a>].</p><p>The challenge of the care team is to work with youth to determine how they want to present their experienced gender to the outside world. Nonbinary-identified youth require providers who are open-minded and skilled at eliciting information that differentiates gender identity from gender expression and can work with youth to develop interventions that meet their individual needs [<a href="#rid19">19,60</a>]. Depending upon their level of discomfort related to the mismatch between gender identity and birth-designated sex, youth with a nonbinary gender identity may or may not want to take GAH; some may desire a low-level dose to maintain a more androgynous effect.</p><p class="headingAnchor" id="H113274158"><span class="h1">OVERVIEW OF HORMONAL INTERVENTIONS FOR ADOLESCENTS</span></p><p class="headingAnchor" id="H65066949"><span class="h2">Potential indications</span><span class="headingEndMark"> — </span>Hormonal interventions to suppress puberty and/or promote development of asserted-gender secondary sexual characteristics may be beneficial in transgender or gender-diverse (TGD) youth whose assertion of gender identity is different from birth-designated sex [<a href="#rid1">1,8,12,39,52,55</a>]. Pubertal suppression also may be beneficial for youth who are exploring a nonbinary identity and have concerns about the irreversible changes of endogenous puberty. Youth with intense feelings of gender dysphoria are at risk for adverse psychosocial outcomes. </p><p>Additional considerations for starting hormonal therapy should include the presence of adequate psychosocial support, understanding of the expected outcomes, medical and social benefits as well as risks of treatment, and whether mental health counseling would be beneficial to the patient. For individuals with adverse mental health sequelae of gender dysphoria that impairs self-esteem and function (eg, activities of daily living), hormonal treatment requires close collaboration with mental health providers. These recommendations are outlined in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.endocrine.org%2Fclinical-practice-guidelines&amp;token=Le2c4RlMYbLQVHkeMqrseO5fsxy712Dl2SKcFtrAKFiUeys0ioH5d90mKdRi40e93BScIuG%2Fc%2FRHy49qT0ph9g%3D%3D&amp;TOPIC_ID=86771" target="_blank">Endocrine Society Clinical Practice Guideline</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.wpath.org%2Fsoc8&amp;token=OqHbRR0lt%2FUEOwSsKCcy78fWPwAZftZUkJq2mRkHvWRFJFmfwFx51LpopOcDs6uu&amp;TOPIC_ID=86771" target="_blank">World Professional Association for Transgender Health (WPATH) Standards of Care</a>, and are similar to recommendations for cisgender youth who are experiencing distress [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H65066871"><span class="h2">Counseling and consent</span><span class="headingEndMark"> — </span>Youth considering hormonal therapy for gender dysphoria and their caregivers must be fully informed of the potential benefits and risks before they can provide informed assent or consent. Mental health benefits and risks are a crucial part of this discussion. Medical contraindications to hormonal therapy are rare in adolescents and young adults.</p><p>Most TGD adolescents are competent to provide informed consent/assent. In a cross-sectional study of 74 transgender adolescents (age 10 to 18 years), 90 percent were assessed competent to consent to pubertal suppression by the MacArthur Competence Assessment Tool for Treatment, a decision-making competence assessment tool with empiric support [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H336508205"><span class="h3">Reversibility</span><span class="headingEndMark"> — </span>The effects of gender-affirming hormones (GAH) are considered partially reversible, in contrast to social transition and gonadotropin-releasing hormone (GnRH) analogs, which are completely reversible. The irreversible effects of GAH often are highly desired (eg, lower voice, male pattern hair, and clitoromegaly for transmasculine youth; breast development for transfeminine youth). These more permanent effects occur gradually, giving clinicians and patients the ability to periodically review how the changes impact the patient's gender identity and feelings of dysphoria. (See <a class="local">'Suppression of endogenous puberty'</a> below and <a class="local">'Gender-affirming hormone therapy'</a> below.)</p><p class="headingAnchor" id="H3777271424"><span class="h3">Fertility considerations</span><span class="headingEndMark"> — </span>When counseling caregivers and TGD youth, it is important to emphasize:</p><p class="bulletIndent1"><span class="glyph">●</span>When TGD persons engage in sexual activity that involves egg and sperm, pregnancy can occur even when GAH are being taken.</p><p></p><p class="bulletIndent1">Contraception is recommended for TGD persons who wish to avoid pregnancy [<a href="#rid63">63,64</a>]. For transmasculine individuals, long-acting reversible contraception (eg, intrauterine device, <a class="drug drug_pediatric" data-topicid="127394" href="/d/drug information/127394.html" rel="external">etonogestrel implant</a>) has superior efficacy and may have desirable side effects such as amenorrhea; exogenous <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> does not prevent pregnancy. (See  <a class="medical medical_review" href="/d/html/107.html" rel="external">"Contraception: Issues specific to adolescents", section on 'Long-acting reversible methods'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>GAH may compromise the ability to have a genetic child in those whose endogenous puberty was suppressed early in puberty. However, increasing consideration regarding fertility preservation for youth receiving puberty blockers in early puberty is occurring in clinical and research settings.</p><p></p><p class="bulletIndent1">Although TGD youth who are treated with GnRH analogs to suppress endogenous puberty in Tanner stage 2 and then switched to GAH generally do not develop sperm or oocytes that are viable for reproduction [<a href="#rid65">65</a>], there are case reports of fertility preservation in transmasculine individuals who had endogenous puberty suppressed [<a href="#rid66">66,67</a>].</p><p></p><p class="bulletIndent1">It is not clear how GAH affect fertility in TGD youth who do not undergo pubertal suppression and initiate GAH later in puberty. In a case series of transmasculine adolescents pursuing fertility preservation, all four who had not received GnRH analogs as part of their gender-affirming care had mature oocytes cryopreserved in each cycle and tolerated stimulation and retrieval [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1">TGD adults have successfully had genetic children [<a href="#rid64">64,68</a>].</p><p></p><p class="bulletIndent1">Transgender persons who wish to optimize their potential for genetic children should consult with a reproductive endocrinologist or urologist regarding their options for fertility preservation (eg, oocyte or sperm preservation, cryopreservation of ovarian or testicular tissue) [<a href="#rid65">65,69-72</a>]. Fertility preservation is expensive and not usually covered by insurers, which limits availability. (See  <a class="medical medical_review" href="/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a> and  <a class="medical medical_review" href="/d/html/121395.html" rel="external">"Fertility preservation: Cryopreservation options"</a>.)</p><p></p><p>Adolescents generally are able to weigh the pros and cons of hormone therapy, including the potential impact on future fertility. In the authors' experience, many transgender youth state that their desire to express their gender authentically supersedes their desire for fertility. They clearly articulate plans to parent, but in their identified gender and using resources such as adoption or reproductive technologies. Surveys of TGD adolescents support the authors' experience, with only 20 to 36 percent expressing interest in biologic parenthood [<a href="#rid73">73-75</a>].</p><p class="headingAnchor" id="H65066886"><span class="h2">Availability of care</span><span class="headingEndMark"> — </span>Hormonal interventions for youth with gender dysphoria may be provided in a variety of settings. Specialized centers with multidisciplinary teams offer coordinated services and may be involved in long-term follow-up and research that will add to the growing body of evidence regarding outcomes [<a href="#rid14">14</a>]. However, it is often difficult for TGD adolescents and their families to find or access care with appropriately trained medical and mental health providers [<a href="#rid11">11,12,76,77</a>]. Multidisciplinary centers are available in a limited number of cities.</p><p>Cost considerations and legislative bans may further limit availability. Insurance coverage for medical interventions varies geographically, and ability to pay out-of-pocket for services that are not covered by insurance may influence treatment options [<a href="#rid78">78,79</a>]. Adolescents who are unable to afford or access hormonal interventions may decide to purchase hormones online or on the street and use them without medical supervision [<a href="#rid80">80,81</a>]. In the United States, some states have legislative bans on gender-affirming care that may result in penalties for clinicians and/or caregivers [<a href="#rid20">20</a>]. (See <a class="local">'Guiding principles'</a> above.)</p><p>When gender specialty centers are not available (which is more often than not), the WPATH standards of care recommend that the clinician providing and monitoring hormonal treatment be well versed in the relevant medical and psychological aspects of treatment [<a href="#rid10">10</a>]. Such clinicians may be board-certified endocrinologists or adolescent medicine specialists, but many gender specialists have other medical backgrounds with additional training in gender and sexual health and adolescent health. Without additional training and expertise, most primary care providers are uncomfortable with initial evaluations and starting youth on hormones. However, to improve access and patient-centered care, primary care providers are instrumental in coordinating care, providing referrals, and providing clinical and laboratory monitoring for patients receiving hormonal interventions. In addition, given the prior relationship with a child and family, primary care providers can be powerful role models for support, positive regard, and acceptance of transition for the youth and family members [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Role of the medical provider'</a>.)</p><p class="headingAnchor" id="H231873"><span class="h2">Suppression of endogenous puberty</span></p><p class="headingAnchor" id="H65067200"><span class="h3">Rationale</span><span class="headingEndMark"> — </span>Suppression of endogenous puberty may be warranted for TGD youth with persistent gender dysphoria that intensifies after the onset of puberty and nonbinary gender-diverse youth who are in the process of determining their gender identity [<a href="#rid1">1,8,12,55,83</a>].</p><p>Gender dysphoria that has been present since childhood and intensifies with the onset of puberty rarely subsides [<a href="#rid1">1,2,55</a>]. Limited follow-up studies of youth who received gender-affirming care at specialized centers that included comprehensive assessment of maturity to make treatment decisions indicate that most youth who receive GnRH analogs subsequently receive GAH therapy [<a href="#rid84">84-86</a>].</p><p>Suppression of puberty may spare TGD youth from increased body dysphoria due to development of the "wrong" and often permanent sex characteristics [<a href="#rid87">87</a>], which may be associated with comorbid symptoms or health risk behaviors (eg, depression, anxiety, self-harm, suicidality, substance use, unprotected sex) [<a href="#rid11">11,83</a>]. Suppression of puberty also "buys time" during which the youth can more fully explore their gender identity with a trained mental health professional. They can work with the mental health professional to make a thoroughly informed decision about medications, surgeries, or other ways to authenticate their gender and to develop resiliency tools to help them cope with the challenges of openly changing their social identity and expression in addition to the other challenges of adolescent development [<a href="#rid88">88</a>].</p><p>The reversibility of pubertal suppression may be comforting for caregivers who need additional time to learn more about gender diversity and care and to come to terms with a different future for their child than the one they may have envisioned [<a href="#rid89">89</a>].</p><p>The potential benefits of pubertal suppression include [<a href="#rid8">8,90-94</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prevention of the development of unwanted secondary sexual characteristics (eg, breast development, menarche/menses; voice deepening, phallic growth, spontaneous erections, unwanted male pattern hair growth), which may interfere with well-being and psychosocial functioning</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clarification of gender identity and the degree of gender dysphoria</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Resumption of endogenous puberty if discontinued; if the decision is made to discontinue GnRH analogs, the youth will progress through endogenous puberty after approximately 12 months – including the development of mature sperm and follicles</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Opportunity to live in the phenotype of the affirmed gender (with concurrent social transition)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Easier, less costly physical affirmation process with improved physical outcomes for patients who decide to proceed with GAH therapy and/or surgery than if they progress through endogenous puberty</p><p></p><p>Evidence from observational studies suggests that suppression of endogenous puberty may help to alleviate psychosocial distress in gender dysphoric youth [<a href="#rid95">95-98</a>]. In prospective follow-up of a cohort of 70 gender dysphoric youth, behavioral and emotional problems, depressive symptoms, and general functioning improved after treatment with GnRH analogs to suppress puberty [<a href="#rid99">99</a>]. However, pubertal suppression alone did not alleviate gender dysphoria, and all of the treated patients elected to proceed with GAH. In another observational study, all patients who underwent pubertal suppression with GnRH analogs were satisfied with their lack of pubertal development, all of those who were eligible for GAH treatment chose to proceed, no adverse effects were noted, and no patients took street hormones [<a href="#rid88">88</a>].</p><p>Longer-term follow-up is necessary to examine whether gender dysphoric adolescents who underwent pubertal suppression with GnRH analogs followed by GAH will be able to maintain their relatively good functioning in their adult years after gender-affirming surgery. In one study with long-term follow-up of 55 patients who underwent puberty suppression (mean age 13.6 years) followed by GAH therapy (introduced at a mean age of 16.7 years) and gender-affirming surgery (mean age 19.2 years), gender dysphoria was alleviated in young adulthood (mean age 20.7 years) and well-being was similar to that in young adults from the general population [<a href="#rid100">100</a>]. In a cross-sectional survey, wanting and receiving puberty suppression during adolescence was associated with decreased rates of self-reported suicidality among &gt;20,000 TGD adults (age 18 to 36 years) [<a href="#rid101">101</a>].</p><p class="headingAnchor" id="H231880"><span class="h3">Timing</span><span class="headingEndMark"> — </span>The patient's desire to halt endogenous puberty and readiness to begin treatment are primary factors when deciding when to begin pubertal suppression. Parental consent and support and whether the patient has entered puberty are additional factors. (See <a class="local">'Counseling and consent'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation before the onset of puberty</strong> – Administration of GnRH analogs before Tanner stage 2 provides no benefit and unnecessary expense. However, administration as soon as possible after puberty begins may provide relief for gender dysphoric youth who have increasing anxiety as puberty approaches. These youth should be assured that they will be closely followed so GnRH analogs can be administered as soon as they are indicated.</p><p></p><p class="bulletIndent1">Providers can confirm the onset of central puberty through physical examination and laboratory studies. Onset of central puberty is indicated by Tanner stage 2 breast buds  (<a class="graphic graphic_picture graphicRef72038" href="/d/graphic/72038.html" rel="external">picture 1A</a>) or testicular/penile enlargement  (<a class="graphic graphic_picture graphicRef80005" href="/d/graphic/80005.html" rel="external">picture 1C</a>). Laboratory evidence of pubertal onset is provided by levels of ultrasensitive luteinizing hormone (LH), follicular stimulating hormone, <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a>, or <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> above prepubertal levels.</p><p></p><p class="bulletIndent1">Although early suppression of puberty may result in inadequate scrotal and penile tissue for traditional penile inversion vulvovaginoplasty techniques, in the authors' experience, the potential benefits of early suppression generally outweigh this concern for transfeminine youth. In addition, newer surgical techniques, including the grafting of other tissues to create a viable vaginal canal, have been improving over time. This concern is included in the discussion of benefits and risks before initiation of pubertal suppression and, later, initiation of <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Presentation after onset of puberty</strong> – Although it is ideal to begin GnRH analogs at early Tanner 2, most youth do not present for medical care at or before this stage of puberty [<a href="#rid1">1</a>]. If initiated at Tanner stage 3 or 4  (<a class="graphic graphic_picture graphicRef72038 graphicRef79782 graphicRef80005" href="/d/graphic/72038.html" rel="external">picture 1A-C</a>), GnRH analogs may prevent continued progression of puberty, maintain androgynous physical features, cause some regression of secondary sexual characteristics, stop menses or erections, and provide psychological relief for a patient who is distressed by cisgendered development [<a href="#rid8">8,88,99</a>]. However, GnRH analogs alone provide little benefit for patients who present in late puberty, when irreversible secondary sexual characteristics are already well developed (eg, breasts, Adam's apple, voice deepening). For such patients, GAH therapy may be more appropriate. (See <a class="local">'Gender-affirming hormone therapy'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transmasculine adolescents</strong> – The use of GnRH analogs in conjunction with GAH allows for the induction of a more peer-concordant male puberty in transmasculine individuals. For example, a 13- or 14-year-old transmasculine adolescent who has already achieved Tanner 5 development might be a good candidate for starting <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a>, but the testosterone dose necessary to suppress menses would result in age-inappropriate masculinization. </p><p></p><p class="bulletIndent2">Concurrent administration of GnRH analogs would suppress menses while allowing peer-concordant masculinization through progressive <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> dose escalation. <a class="drug drug_pediatric" data-topicid="12577" href="/d/drug information/12577.html" rel="external">Medroxyprogesterone acetate</a> injections, the 52 mg levonorgestrel-releasing intrauterine device (<a class="drug drug_pediatric" data-topicid="127810" href="/d/drug information/127810.html" rel="external">LNg IUD</a>), or oral <a class="drug drug_pediatric" data-topicid="12652" href="/d/drug information/12652.html" rel="external">norethindrone</a> may be an alternative for menstrual suppression [<a href="#rid102">102</a>]. Both medroxyprogesterone acetate and the LNg IUD provide the added benefit of contraception, which norethindrone does not. (See  <a class="medical medical_review" href="/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection", section on 'Reasons to choose an LNG IUD'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Transfeminine adolescents</strong> – Transfeminine individuals who present in late puberty can also benefit from concurrent GnRH analogs and GAH. Reduction in androgen production by central LH suppression (via GnRH analogs) is far superior to peripheral blockade of androgen synthesis and action (eg, <a class="drug drug_general" data-topicid="8447" href="/d/drug information/8447.html" rel="external">finasteride</a>, <a class="drug drug_pediatric" data-topicid="12803" href="/d/drug information/12803.html" rel="external">spironolactone</a>). Transfeminine individuals frequently can be feminized with lower doses of estrogen if they receive concurrent GnRH analogs (regardless of sexual maturity rating).</p><p></p><p class="headingAnchor" id="H231888"><span class="h3">Regimen</span><span class="headingEndMark"> — </span>Suppression of puberty can be achieved with the use of GnRH analogs, antiandrogens, antiestrogens, and <a class="drug drug_pediatric" data-topicid="12577" href="/d/drug information/12577.html" rel="external">medroxyprogesterone acetate</a> [<a href="#rid8">8,95,103,104</a>]. GnRH analogs are usually preferred because of their efficacy, safety profile, and clinical experience in treating children with precocious puberty [<a href="#rid104">104-107</a>]. (See  <a class="medical medical_review" href="/d/html/16318.html" rel="external">"Treatment of precocious puberty", section on 'Formulations and dosing'</a>.)</p><p>The availability of GnRH analogs and coverage by insurance varies geographically [<a href="#rid78">78</a>]. Medication regimens are not standardized. The protocol suggested in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.endocrine.org%2Fclinical-practice-guidelines&amp;token=Le2c4RlMYbLQVHkeMqrseO5fsxy712Dl2SKcFtrAKFiUeys0ioH5d90mKdRi40e93BScIuG%2Fc%2FRHy49qT0ph9g%3D%3D&amp;TOPIC_ID=86771" target="_blank">Endocrine Society Clinical Practice Guideline</a> was developed by the Center of Expertise on Gender Dysphoria (formerly the Amsterdam Gender Clinic) and is endorsed by the Australasian Paediatric Endocrine Group [<a href="#rid8">8,35,88,108</a>]. This protocol and others adapted from it have demonstrated suppression of puberty without adverse effects in small cohorts of patients [<a href="#rid2">2,3,99</a>].</p><p>GnRH analogs may be administered in a variety of forms, including injections and implants  (<a class="graphic graphic_table graphicRef72979" href="/d/graphic/72979.html" rel="external">table 3</a>). In our experience, most adolescents start with the <a class="drug drug_pediatric" data-topicid="87619" href="/d/drug information/87619.html" rel="external">histrelin</a> implant (effective for two years or longer [<a href="#rid109">109</a>]) or with intramuscular <a class="drug drug_pediatric" data-topicid="12545" href="/d/drug information/12545.html" rel="external">leuprolide</a> injections every three months. The dose of the injection may be titrated to adequately suppress puberty by patient report, physical examination, and/or laboratory values. (See <a class="local">'Monitoring during pubertal suppression'</a> below.)</p><p>GnRH analogs ideally are continued concurrently with GAH until patients can receive gonadectomies [<a href="#rid8">8</a>]. However, they usually are discontinued earlier. Prolonged suppressive therapy with GnRH analogs is expensive, may not be covered by insurance, and may be unaffordable or unavailable for patients [<a href="#rid78">78,92</a>]. Alternatives to the ideal regimen include either:</p><p class="bulletIndent1"><span class="glyph">●</span>Continuing GnRH analogs over one to two years as GAH doses are titrated and approach adult levels, or</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Discontinuing GnRH analogs after one to two years and while quick-starting adult-dose GAH therapy</p><p></p><p>Timing of GAH administration and puberty in the youth's identified gender generally should be aligned with puberty initiation and development consistent with their peers, although the youth's height goal is another consideration. (See <a class="local">'Timing'</a> below.)</p><p class="headingAnchor" id="H3482717650"><span class="h3">Monitoring during pubertal suppression</span><span class="headingEndMark"> — </span>Monitoring youth during pubertal suppression allows providers to assess mental and physical health, to counsel about potential adverse effects, and to continue to discuss the affirmation plan with youth and their families. Parameters to be monitored include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Growth (height, weight</strong>) – Pubertal suppression alters the timing of the pubertal growth spurt and delays fusion of the growth plates, which may affect adult height [<a href="#rid88">88,95</a>].</p><p></p><p class="bulletIndent1">Monitoring height (including height velocity and height curves) every three months during pubertal suppression may inform interventions that help achieve the youth's height goals (eg, prevention of excessively tall stature for transfeminine patients, maximal height for transmasculine patients). However, in a small retrospective study, receipt of early pubertal suppression followed by GAH at age 16 years in both transfeminine and transmasculine youth did not significantly impact final adult height based on pretreatment predictions [<a href="#rid110">110</a>]. The mean maternal and paternal height, adjusted for sex assigned at birth, was the best predictor of final height.</p><p></p><p class="bulletIndent1">Weight should be monitored regularly because unwanted weight gain may occur with the use of GnRH agonists.</p><p></p><p class="bulletIndent1">We do not monitor bone age (eg, radiograph of the left hand). However, some experts obtain bone age annually in youth who are concerned about final height. Bone age radiographs and timing of closure of epiphyseal plates can help determine where the youth is in their growth trajectory.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pubertal progression</strong> – Asking whether puberty is progressing is the most important way to monitor the effectiveness of pubertal suppression therapy.</p><p></p><p class="bulletIndent1">Providers may measure endogenous sex hormone levels (using ultrasensitive <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> or <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> assays) and gonadotropin levels (using pediatric LH assays) at baseline and every six months to assure adequate suppression into the prepubertal range (which may vary from laboratory to laboratory) or to reassure patients that suppression is effective. Ultrasensitive sex steroid levels are the best indicator of suppression.</p><p></p><p class="bulletIndent1">Measurement of endogenous sex hormone levels and gonadotropin levels is also warranted if patients report symptoms of pubertal change. If the gonadal axis is not completely suppressed, the interval between GnRH analog injections may need to be shortened or the dose increased.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bone health</strong> – Decreased bone mineral density (BMD) accrual is a potential risk of pubertal suppression because accretion of BMD is suspended during GnRH analog therapy alone (ie, prior to addition of GAH). There is limited information about long-term bone health among TGD youth who are treated with GnRH analogs and gender-affirming hormones or whether maintaining physiologic levels of gender hormones in adulthood is associated with improved BMD.</p><p></p><p class="bulletIndent1">The best data come from one cohort study that assessed lumbar spine, femoral neck, and total hip BMD z-scores of 75 participants (25 assigned female at birth, 50 assigned male at birth) at three time points: start of GnRH analog therapy; start of GAH; and follow-up at least nine years after initiation of GAH therapy [<a href="#rid111">111</a>]. Median BMD z-scores returned to baseline at the long-term follow-up visit, with the exception of lumbar spine z-scores in participants assigned male at birth. Their median serum <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> level at nine years was 59 pg/mL, which may be insufficient for optimal bone accrual.</p><p></p><p class="bulletIndent1">Another concern is that baseline BMD of TGD youth is frequently lower than reference standards for sex assigned at birth, particularly for transgender girls [<a href="#rid112">112-114</a>], and this may be compounded by lack of return to baseline BMD at the lumbar spine [<a href="#rid111">111</a>]. In earlier observational studies of TGD youth treated with GnRH analogs, the addition of GAH was associated with increased BMD at short-term follow-up, partially compensating for decreased accretion during GnRH analog therapy alone [<a href="#rid88">88,115-117</a>]. In children treated with GnRH analogs for precocious puberty, bone mass is regained after cessation of treatment and peak bone mass is normal. (See  <a class="medical medical_review" href="/d/html/16318.html" rel="external">"Treatment of precocious puberty", section on 'Monitoring'</a>.)</p><p></p><p class="bulletIndent1">The Endocrine Society and WPATH recommend monitoring bone density annually for youth receiving GnRH analogs. In particular, TGD youth with restrictive eating disorders, chronic glucocorticoid use, or other risk factors for decreased BMD or osteoporosis may benefit from monitoring BMD over time, particularly if they may receive GnRH analogs without GAH for ≥2 years. Addition of GAH may be warranted if bone density z-score decreases substantially, although other factors are more important in the decision to initiate GAH. (See <a class="local">'Timing'</a> below.)</p><p></p><p class="bulletIndent1">Although the authors of this topic do not routinely monitor vitamin D levels, they provide vitamin D and calcium supplementation for adolescents (independent of gender identity) with risk factors for vitamin D deficiency (eg, insufficient intake, poor sunlight exposure, dark skin). Other experts may measure vitamin D levels and prescribe vitamin D to patients with documented low levels to encourage adherence with supplementation. (See  <a class="medical medical_review" href="/d/html/14590.html" rel="external">"Vitamin D insufficiency and deficiency in children and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mental health and other effects related to hormonal changes</strong> – Patients undergoing pubertal suppression should be monitored regularly for mental health and other effects related to hormonal changes:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transmasculine and transfeminine patients who are started on GnRH analogs well into puberty (ie, Tanner stage 3 to 5) may experience hot flashes, mood disruption, and loss of libido [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transmasculine patients also may have signs and symptoms related to rapid withdrawal of sex hormones (eg, withdrawal bleeding and disruption of menstrual cycles) [<a href="#rid88">88</a>]. Patients and caregivers should be alerted to potential irritability, depression, and other symptoms of menopause [<a href="#rid118">118</a>].</p><p></p><p class="bulletIndent1">Patients with serious mental health effects (eg, depression) require close monitoring. In the authors' experience, it is beneficial to prepare patients for potential changes in feelings or thoughts related to hormonal interventions – starting with the probable positive changes (eg, relief, decreased hopelessness, decreased suicidality) followed by the less likely negative changes (eg, irritability, moodiness, fatigue). This discussion also makes explicit the need for accurate reporting of adverse mental health effects.</p><p></p><p class="headingAnchor" id="H231909"><span class="h2">Gender-affirming hormone therapy</span></p><p class="headingAnchor" id="H176168012"><span class="h3">Pretreatment considerations</span><span class="headingEndMark"> — </span>Treatment with GAH is necessary to induce secondary sex characteristics that are aligned with the patient's asserted gender and to maintain asserted-gender phenotypic appearance. Some of the phenotypic changes that are attained with GAH therapy are reversible and others are not. (See <a class="local">'Transfeminine persons'</a> below and <a class="local">'Transmasculine persons'</a> below.)</p><p>Access to GAH therapy for TGD youth who would like to receive it is associated with lower rates of anxiety, depression, and suicidality [<a href="#rid119">119,120</a>].</p><p>Additional considerations before initiation of gender-affirming hormonal therapy include ensuring that the adolescent [<a href="#rid8">8,10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Has adequate psychosocial support.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Assents to treatment, understanding the expected outcomes and the medical and social risks and benefits (as with any medication); some centers require a letter from a mental health provider who has determined that the youth would benefit from gender-affirming hormonal therapy; other centers do not.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Will take GAH in a responsible manner (as with any medication).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Has no contraindications to GAH (most of which are uncommon in adolescents):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transfeminine individuals – For transfeminine individuals, estrogen-sensitive tumors are a contraindication; increased risk for venous thromboembolism (VTE) and severe liver dysfunction are precautions.</p><p></p><p class="bulletIndent2">Coexisting medical problems that increase baseline risk of VTE are usually not considered contraindications to <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> because there are no other medication options for feminizing therapy. The potential (but unquantifiable) risk of VTE must be balanced with the <strong>known</strong> risks of negative health outcomes (eg, self-harm, suicide) in transgender individuals who are not supported in their transition. </p><p></p><p class="bulletIndent2">Treatment plans should focus on efforts to minimize other VTE risk factors. Transfeminine people with migraine with aura or other neurologic symptoms, uncontrolled hypertension, and other conditions that cause excessive blood clotting should understand that the relative risk of VTE is increased with use of <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> but that the absolute risk of VTE for each patient is unknown. GAH therapy with 17-beta estradiol is administered at physiologic doses and considered less thrombogenic than the supraphysiologic doses of ethinyl estradiol in the original studies identifying increased risk of VTE for hormone replacement therapy or contraception [<a href="#rid121">121,122</a>]. When prescribing 17-beta estradiol for gender-affirming therapy, providers can minimize the risk of VTE by using nonoral routes (eg, dermal, sublingual, injectable) and titrating to physiologic concentrations [<a href="#rid123">123</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transmasculine individuals – For transmasculine individuals, testosterone-sensitive tumors, pre-existing problematic polycythemia, and severe chronic liver dysfunction are contraindications.</p><p></p><p>These requirements are outlined in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.endocrine.org%2Fclinical-practice-guidelines&amp;token=Le2c4RlMYbLQVHkeMqrseO5fsxy712Dl2SKcFtrAKFiUeys0ioH5d90mKdRi40e93BScIuG%2Fc%2FRHy49qT0ph9g%3D%3D&amp;TOPIC_ID=86771" target="_blank">Endocrine Society Clinical Practice Guideline</a> [<a href="#rid8">8</a>] and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.wpath.org%2Fsoc8&amp;token=OqHbRR0lt%2FUEOwSsKCcy78fWPwAZftZUkJq2mRkHvWRFJFmfwFx51LpopOcDs6uu&amp;TOPIC_ID=86771" target="_blank">WPATH Standards of Care</a> [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H231923"><span class="h3">Timing</span><span class="headingEndMark"> — </span>The timing of initiation of GAH in adolescents is individualized.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adolescents who have undergone pubertal suppression</strong> – The optimal timing for GAH therapy is uncertain; evidence from long-term studies is limited. For adolescents who have undergone pubertal suppression, protocols from the Netherlands recommend initiation of GAH to induce affirmed-gender puberty at age 16 years, which is the legal age of consent in the Netherlands and several other European countries [<a href="#rid1">1,2,8,11,88</a>]. The guidelines from the Endocrine Society and the WPATH acknowledge that there may be compelling reasons to initiate GAH before age 16 years [<a href="#rid8">8,10</a>]. Earlier initiation may be warranted for certain patients, including:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Those whose gender identity is well established and stable at an early age</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pubertal adolescents who report gender dysphoria, a transgender identity, or a gender identity that would benefit from GAH</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transfeminine patients with tall stature (for earlier closure of the growth plates)</p><p></p><p class="bulletIndent1">In addition, earlier initiation of GAH therapy may avoid prolonged pubertal suppression, which may be associated with decreased BMD [<a href="#rid10">10</a>]. Initiation of GAH at a time similar to pubertal onset in age-matched peers (ie, before 16 years of age) also may have psychosocial benefits. Given the importance of peer congruence during the high school years, it is reasonable to assume that a 16 year old with the sexual development of a 10 year old may suffer some psychological distress – although this has not been formally evaluated in clinical studies. Observational studies suggest that constitutional delay of growth and puberty is associated with adverse psychosocial effects, including [<a href="#rid124">124</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Incompetence and vulnerability</p><p class="bulletIndent2"><span class="glyph">•</span>Impaired self-esteem</p><p class="bulletIndent2"><span class="glyph">•</span>Reluctance to participate in athletic activities</p><p class="bulletIndent2"><span class="glyph">•</span>Social isolation</p><p class="bulletIndent2"><span class="glyph">•</span>Impaired academic performance</p><p class="bulletIndent2"><span class="glyph">•</span>Substance abuse</p><p class="bulletIndent2"><span class="glyph">•</span>Disruptive and suicide behavior</p><p></p><p class="bulletIndent1">Initiation of GAH that is more congruent with peers' average age of puberty (ie, age 12 to 13 years for females and age 13 to 14 years for males) also can decrease the financial burden for patients and families if suppression of puberty with GnRH is discontinued when GAH are started. In the United States (where <a class="drug drug_pediatric" data-topicid="120073" href="/d/drug information/120073.html" rel="external">triptorelin</a> is not a labeled indication for pubertal suppression), suppression of puberty with GnRH analogs is more expensive than GAH and may not be covered by insurance [<a href="#rid78">78</a>], whereas GAH often are covered by insurance plans or available at the substantially discounted medication programs offered by various national pharmacies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adolescents who have not undergone pubertal suppression</strong> – Adolescents with gender dysphoria who have not undergone pubertal suppression may begin GAH therapy if they would benefit from GAH, have a healthy and safe affirmation plan, and are ready to begin their second puberty [<a href="#rid1">1,11</a>]. (See <a class="local">'Pretreatment considerations'</a> above.)</p><p></p><p class="bulletIndent1">If GAH therapy started after puberty is complete or near-complete, it may not affect certain phenotypic characteristics [<a href="#rid11">11</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transfeminine youth – The administration of estrogen and androgen blockers will not affect voice pitch, laryngeal prominence (Adam's apple), height, and skeletal features, or eliminate male pattern facial and body hair.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Transmasculine youth – The administration of <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> will not reduce the size of or remove breast tissue.</p><p></p><p class="bulletIndent1">The development/persistence of undesired, permanent phenotypic characteristics highlights the importance of screening for and early identification of gender diversity in prepubertal children. (See  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Identification'</a>.)</p><p></p><p class="headingAnchor" id="H231937"><span class="h3">Transfeminine persons</span><span class="headingEndMark"> — </span>Exogenous 17-beta <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> is necessary for feminization of birth-designated males. The addition of androgen blockers (eg, <a class="drug drug_pediatric" data-topicid="12803" href="/d/drug information/12803.html" rel="external">spironolactone</a>, <a class="drug drug_general" data-topicid="9154" href="/d/drug information/9154.html" rel="external">bicalutamide</a>, or <a class="drug drug_general" data-topicid="8447" href="/d/drug information/8447.html" rel="external">finasteride</a>) assists in reducing <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> activity and/or male-pattern hair.</p><p>The primary aims of estrogen therapy are  (<a class="graphic graphic_table graphicRef54189" href="/d/graphic/54189.html" rel="external">table 4</a>) [<a href="#rid8">8,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Development of breasts (irreversible) and female fat distribution pattern (reversible)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Softening of the skin (reversible)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Maintenance of a higher-pitch voice (provided that puberty was blocked; estrogen will not cause a voice change if the voice has already deepened)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decrease/avoidance of male pattern body and facial hair (partially reversible)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoidance of masculine skeletal changes that occur with <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> during puberty</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Decrease in testicular mass (which may make it easier to tuck the testicles into the inguinal canal; unknown if reversible)</p><p></p><p>GAH regimens to induce puberty and to maintain cross-gender sexual characteristics are available from professional groups and centers of excellence for transgender care [<a href="#rid6">6,8,10</a>]. These regimens assume continued treatment with GnRH analogs. Increasing the <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> dose gradually may prevent striae and abnormal breast shape. For patients who are not continuing GnRH analogs, the dose of estrogen will need to be increased (approximately doubled) to achieve development of female secondary sexual characteristics and suppress endogenous <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a>.</p><p>Estrogen is available in oral, sublingual, topical (patch), intramuscular and subcutaneous injections, or intradermal pellet preparations [<a href="#rid125">125</a>]. The oral formulation of 17-beta <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> administered sublingually is most commonly used because blood levels can be monitored and it is associated with a lower risk of thromboembolic events than other estrogens (eg, ethinyl estradiol) [<a href="#rid126">126</a>]. However, some adolescents prefer injections of 17-beta estradiol every one to two weeks.</p><p><a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">Estradiol</a> therapy is effective in inducing breast development and female fat distribution in TGD adolescents [<a href="#rid95">95</a>]. In a review of 28 adolescents who received gender-affirming pubertal induction with estradiol for at least one year, breast development started within three months in 15 of 18 girls for whom data were available, and 12 of 14 achieved stage 4 to 5 sexual maturity rating breast development within three years [<a href="#rid127">127</a>].</p><p>There is little information about the frequency of adverse effects in adolescents receiving GAH [<a href="#rid1">1,2,12</a>]. In several small case series and a multicenter analysis of electronic health records, gender-affirming <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> therapy in adolescent patients has not been associated with severe complications or metabolic abnormalities (eg, hypertension; increased body mass index [BMI]; electrolyte disturbances; elevated creatinine, liver enzymes, lipids, hemoglobin/hematocrit, hemoglobin A1C) [<a href="#rid91">91,95,127-130</a>]. However, in long-term follow-up, the prevalence of obesity at age 22 years was more common among transfeminine youth who were treated with GnRH analogues at age 15 and GAH at age 17 years than among their cisgender peers (9.9 percent versus 2.2 percent) [<a href="#rid129">129</a>].</p><p class="headingAnchor" id="H231944"><span class="h3">Transmasculine persons</span><span class="headingEndMark"> — </span>Exogenous <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> is necessary for masculinization of birth-designated females. The primary aims of testosterone therapy are  (<a class="graphic graphic_table graphicRef75101" href="/d/graphic/75101.html" rel="external">table 5</a>) [<a href="#rid8">8,11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Suppression of menstruation and breast development (reversible)</p><p class="bulletIndent1"><span class="glyph">●</span>Clitoral enlargement (irreversible)</p><p class="bulletIndent1"><span class="glyph">●</span>Deepening of the voice (irreversible)</p><p class="bulletIndent1"><span class="glyph">●</span>Development of male pattern body and facial hair (partially reversible)</p><p class="bulletIndent1"><span class="glyph">●</span>Increase in lean muscle mass (reversible)</p><p></p><p>GAH regimens to induce puberty and to maintain cross-gender sexual characteristics are available from professional groups and centers of excellence for transgender care [<a href="#rid6">6,8,10</a>]. These regimens assume continued treatment with GnRH analogs. For patients who are not using or continuing GnRH analogs, the dose of <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> will need to be increased to achieve development of male secondary sexual characteristics and suppress endogenous estrogen.</p><p><a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">Testosterone</a> is available as an injection (subcutaneous or intramuscular) or topically (eg, patch, gel, cream) and orally in the United States; no data are available about the use of oral testosterone in transmasculine individuals. Testosterone is most commonly delivered subcutaneously on a weekly schedule. Subcutaneous administration is used by many providers because it is better tolerated, less painful, and as efficacious as intramuscular injection [<a href="#rid131">131</a>]. Intramuscular injections may be dosed every one or two weeks. Topical and oral preparations have unpredictable absorption, which makes dosing and monitoring difficult. Another disadvantage of topical preparations is that they may be inadvertently absorbed by another person through skin-to-skin contact, potentially causing unintended masculinization. Compounding pharmacies can create small-volume, highly concentrated creams that require daily dosing but are less likely to transfer to another person.</p><p>Other preparations of <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> may be preferable for patients with poor adherence, needle phobia, or needle fatigue. This includes autoinjectable testosterone administered weekly, deep intramuscular injectable testosterone administered every two to three months, or subdermally implanted testosterone pellets.</p><p>Transmasculine youth who are starting GAH in early or middle adolescence may not necessarily desire profuse body hair, so they may benefit from starting at a low dose and increasing slowly. On the other hand, too slow or too low a dose may not be sufficient to suppress endogenous estrogen and may allow continued and undesired menstruation or breast development.</p><p>There is little information about the frequency of adverse effects in adolescents receiving GAH [<a href="#rid1">1,2,12</a>]. In case series of transmasculine adolescents, adverse effects generally were mild and did not lead to permanent discontinuation of therapy [<a href="#rid91">91,128</a>]. Adverse effects included acne, male pattern baldness, mild dyslipidemia, mood swings, increased BMI, increased hemoglobin/hematocrit, and decreased high-density lipoprotein levels. In a longitudinal study, the prevalence of obesity at age 22 years was more common among transmasculine youth who were treated with GnRH analogues at age 15 and GAH at age 17 years than among their cisgender peers (6.6 percent versus 3.0 percent) [<a href="#rid129">129</a>]. In other case series, gender-affirming <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> therapy was not associated with changes in blood pressure, prolactin, electrolytes, liver function tests, or hemoglobin A1C [<a href="#rid95">95,132</a>].</p><p>Transmasculine individuals who are having receptive vaginal sex with people with penises (ie, sperm and egg sex) should be advised that <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> administration will not prevent pregnancy even if the patient is amenorrheic. Effective contraceptives and condom use are recommended to prevent pregnancy and sexually transmitted infections (STIs). The 52 mg <a class="drug drug_pediatric" data-topicid="127810" href="/d/drug information/127810.html" rel="external">LNg IUD</a> and etonogestrel implants are alternative methods of contraception that also may suppress menses but will not prevent STIs [<a href="#rid102">102</a>]. (See  <a class="medical medical_review" href="/d/html/5419.html" rel="external">"Intrauterine contraception: Candidates and device selection", section on 'Which LNG IUD?'</a> and  <a class="medical medical_review" href="/d/html/3266.html" rel="external">"Contraception: Etonogestrel implant"</a>.)</p><p>Other options for contraception and factors in the choice of contraceptive method are discussed separately. (See  <a class="medical medical_review" href="/d/html/107.html" rel="external">"Contraception: Issues specific to adolescents", section on 'Choosing a method'</a>.)</p><p class="headingAnchor" id="H113274249"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Patients undergoing GAH therapy should return approximately every three months for the first year of treatment to assure that their hormones are meeting desired goals, levels are within desirable physiologic ranges, and that they are avoiding untoward effects. If the patient is progressing well into their transgender puberty and having no untoward side effects, providers may decrease the frequency to every six months or year thereafter.</p><p>During the induction of puberty, the following examinations and laboratory tests are recommended:</p><p class="bulletIndent1"><span class="glyph">●</span>Height and weight – Every three months during the first year of treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">Testosterone</a> or <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> levels – May be monitored to evaluate adequacy of dosing and/or adherence. Use of liquid chromatography/tandem mass spectrometry (if available) may reduce cross-reactivity and increase accuracy.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For weekly subcutaneous or bimonthly intramuscular <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> injections, total testosterone levels should be interpreted based on the timing of the dose (eg, peak, mid, trough).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients taking estradiol-containing preparations, <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> levels can be variable and difficult to interpret. However, measurement of estradiol levels may be helpful for patients who are taking higher-than-recommended doses of estradiol and are at risk for VTE, or for those with subtherapeutic levels who may benefit from increased doses.</p><p></p><p class="bulletIndent1">We use <a class="drug drug_pediatric" data-topicid="12827" href="/d/drug information/12827.html" rel="external">testosterone</a> and <a class="drug drug_pediatric" data-topicid="13282" href="/d/drug information/13282.html" rel="external">estradiol</a> levels to adjust dosing according to patient goals, clinical changes, average physiologic levels, and avoidance of side or adverse effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal function, liver function, lipids, glucose, insulin, hemoglobin A1C – Yearly or as indicated; more frequent monitoring of these tests in TGD adolescents is not necessary solely because they are taking GAH but may be warranted if clinically indicated. (See <a class="local">'Transfeminine persons'</a> above and <a class="local">'Transmasculine persons'</a> above.)</p><p></p><p class="bulletIndent1">Following induction of gender-affirming puberty, we monitor patients clinically and obtain laboratory studies as clinically indicated. Observational studies suggest that liver function tests and blood chemistry are largely unaffected by GAH therapy in adolescents [<a href="#rid128">128,132</a>].</p><p></p><p class="headingAnchor" id="H231967"><span class="h1">SURGICAL INTERVENTIONS</span><span class="headingEndMark"> — </span>Gender-affirming surgeries (formerly surgical sex reassignment) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Male chest reconstruction (ie, removal of female breasts and construction of a more masculine-appearing chest) for transmasculine persons or nonbinary persons with severe chest dysphoria [<a href="#rid46">46</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Breast augmentation for transfeminine persons</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genital reconstruction surgery:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Creation of a neophallus and testicular implants</p><p class="bulletIndent2"><span class="glyph">•</span>Vulvovaginoplasty and orchiectomy</p><p></p><p>In the United States, insurance preauthorization for gender-affirming surgery in adolescents &lt;18 years of age typically requires substantial documentation, but does occur, especially for transmasculine persons with chest dysphoria.</p><p>Gender-affirming surgery is discussed separately. (See  <a class="medical medical_review" href="/d/html/114516.html" rel="external">"Gender-affirming surgery: Female to male"</a> and  <a class="medical medical_review" href="/d/html/114517.html" rel="external">"Gender-affirming surgery: Male to female"</a>.)</p><p class="headingAnchor" id="H676314674"><span class="h1">TRANSITION TO ADULT CARE</span><span class="headingEndMark"> — </span>The transition from pediatric care to adult care can cause anxiety for the transgender or gender-diverse (TGD) young adult. The new primary care provider may not prescribe hormones, necessitating two transitions for the young person. Patients' concerns include finding a provider who is transgender friendly and whose office is not transphobic, starting over with and developing trust in an unfamiliar provider, and maintaining continuity of hormone care while transitioning to a new office [<a href="#rid133">133</a>]. These and other concerns may adversely affect the mental health of the TGD young adult.</p><p>Consequently, the pediatric clinician should actively facilitate, whenever possible, a transition to a practice that is TGD competent and welcoming. Knowing the providers and staff to whom the clinician is referring the young person can increase the patient's confidence in their transfer of care. This may require establishing contacts with TGD-welcoming and competent adult practices<em>.</em></p><p class="headingAnchor" id="H233854"><span class="h1">RESOURCES</span><span class="headingEndMark"> — </span>Resources for patients, families, and providers include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aap.org%2Fen%2Fpatient-care%2Flgbtq-health-and-wellness%2Fa-pediatricians-guide-to-an-lgbtq-friendly-practice%2F&amp;token=%2BGFQuBIqbPc9UkKWuslXCF5OP%2B%2FAz9iVl1aOeNFl4poKPG%2F2DbcwzQgomGUdA2%2Fj66mCjo3cZJsK8IBA7yQdqrscymqxNLUhvs%2Bbb4UEe2HcvL0rR%2FiVwrMwvm8wrZewrwC1JCwUsNIWoeWxLU0oqw%3D%3D&amp;TOPIC_ID=86771" target="_blank">American Academy of Pediatrics: A Pediatrician's Guide to an LGBTQ+ Friendly Practice</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.childrensnational.org%2Fget-care%2Fdepartments%2Fgender-development-program%2Ffamily-resources%2Ffaqs-about-the-gender-and-sexuality-development-program&amp;token=gg233cyomxN45UuWSZoiE%2BlxLQs9O7S7AF9UXiaE3Z0RbpNjtG8kDSlLAg1yYgZoBHImlTjMsmSmHfHDSKsRPIkexPEMB7va%2FCEYITpUF3e5QgF%2BIuYxpWCvRRzu0UuJNoNyg4YeJkDnLJ4hl1H3uw%3D%3D&amp;TOPIC_ID=86771" target="_blank">Children's National Health System Gender Development Program</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgenderandparenting.squarespace.com%2F&amp;token=%2B%2FSHuG9R5xuQD8%2B8GKuigaEbKpS3LbTqqIzak5j693JqB9Fwyr%2BqSof1QZRMufW3OCZ8Singjv0hFPxD%2BXM0Rw%3D%3D&amp;TOPIC_ID=86771" target="_blank">Expert Consensus Guidelines for Parents and Caregivers: Navigating Early Childhood Gender Identity and Expression</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.genderspectrum.org%2F&amp;token=F%2F33Yq3Lpx4WKgz%2BcwHiE0h3eMZyR9aYa5r6SYnTgiWTKu%2BjvvoXRiZ4x3aB4Paf&amp;TOPIC_ID=86771" target="_blank">Gender Spectrum</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.mchlibrary.org%2Fprofessionals%2Flgbtq.php&amp;token=uDzN8ZjmHw%2BbakHDm8ZM%2FWX8u7yynr5E34zDqYPyuz8sJi%2FwaVr30RCaPtJ9ysUdUpriDpX3%2FOHNJIejg%2Br%2FYg%3D%3D&amp;TOPIC_ID=86771" target="_blank">National Center for Education in Maternal and Child Health at Georgetown University</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fgraduate.lclark.edu%2Fprograms%2Fcontinuing_education%2Ftransactive%2F&amp;token=YjAmGrBdGUIbhWmviMgrrazLWJLiEfAST0InGP46nriAZjAFLxNyom6a1TmgSoNC3w9W%2FBvgIUTu4wG54tVE9GvG4SnZGNTOCPKzUz1yjXI%3D&amp;TOPIC_ID=86771" target="_blank">TransActive</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.imatyfa.org%2F&amp;token=McmUHzbivMBbVmUkgiAMB5ZAvBlXpyjSzAL%2F4EIrTuE%3D&amp;TOPIC_ID=86771" target="_blank">TransYouth Family Allies</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fprevention.ucsf.edu%2Ftranshealth%2Fresources&amp;token=Da2PZEn3xor9dz69PcBPP5Z4%2B%2Fzo%2Bg6iwB1gi6%2FqB8Ok4FoQBStidZPVmoGuBy%2BYj1Mb7yQpI07s1GOCST1MjA%3D%3D&amp;TOPIC_ID=86771" target="_blank">University of California, San Francisco Center of Excellence for Transgender Health</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.wpath.org%2F&amp;token=OqHbRR0lt%2FUEOwSsKCcy75BvTLrFQHvIsOThK%2BOQWn4%3D&amp;TOPIC_ID=86771" target="_blank">World Professional Association for Transgender Health</a></p><p></p><p>Books for children, adolescents, families, and therapists are listed in the table  (<a class="graphic graphic_table graphicRef140953" href="/d/graphic/140953.html" rel="external">table 6</a>)</p><p class="headingAnchor" id="H2061444869"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/117789.html" rel="external">"Society guideline links: Transgender health"</a> and  <a class="medical medical_society_guidelines" href="/d/html/117836.html" rel="external">"Society guideline links: Adolescent sexual health and pregnancy"</a>.)</p><p class="headingAnchor" id="H233773"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – The information provided in this topic is intended to allow primary care providers to educate and support patients and families of patients with gender diversity and to coordinate care, provide referrals, and monitor patients receiving care from specialists. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Guiding principles</strong> – Management for transgender or gender-diverse (TGD) youth is determined according to the individual's gender development, needs, and goals. The safety and well-being of the youth and their family members is foremost. (See <a class="local">'Guiding principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mental health interventions</strong> – Treatment options may be influenced by family expectations, cultural differences, opinions of health professionals, insurance coverage, and availability of services. We support an affirming mental health approach. Reparative therapies, which claim to "cure" transgender identity, are considered unhelpful and potentially harmful by most professional organizations. (See <a class="local">'Mental health interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phenotypic interventions</strong> – Phenotypic interventions include social transition and affirmation (ie, living partially or completely in the preferred gender role by adapting hairstyle, clothing, pronouns, and possibly a new name) and hormonal interventions to suppress endogenous puberty and/or alter secondary sexual characteristics. (See <a class="local">'Hormonal interventions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach in prepubertal children</strong> – Given the unpredictability of the trajectory of gender diversity in prepubertal children, it seems reasonable for the primary care provider to offer education, support, and referral to mental health providers as indicated for those with evidence of gender dysphoria; coexisting anxiety, depression, or suicidality; or serious interpersonal conflicts with peers (eg, bullying) or parents/caregivers. (See <a class="local">'Approach in prepubertal children'</a> above and <a class="local">'Indications for mental health referral'</a> above and  <a class="medical medical_review" href="/d/html/83665.html" rel="external">"Gender development and clinical presentation of gender diversity in children and adolescents", section on 'Role of the medical provider'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach in pubertal children and adolescents</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Gender dysphoria that persists through the onset of puberty or is increased at the onset of puberty is unlikely to subside. For adolescents with gender dysphoria, most gender specialists suggest a supportive, affirming approach with an interdisciplinary team that includes medical and mental health specialists. The management needs and goals differ from adolescent to adolescent. (See <a class="local">'Approach in pubertal children and adolescents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>To allow time for the adolescent to develop the maturity necessary to make a thorough and informed decision about permanent physical changes, medical interventions generally progress from reversible (eg, social transition, pubertal suppression), to partially reversible interventions (eg, gender-affirming hormones), to irreversible interventions (eg, surgical interventions). (See <a class="local">'Approach in pubertal children and adolescents'</a> above and <a class="local">'Social transition'</a> above and <a class="local">'Overview of hormonal interventions for adolescents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hormonal interventions to suppress puberty and/or promote development of cross-gender secondary sexual characteristics may be beneficial for TGD youth whose desire to be of the other gender is persistent, consistent, and intensifies with the onset of pubertal changes and for youth who are exploring a nonbinary identity with concerns about potential irreversible changes if they immediately proceed on time through their endogenous puberty. (See <a class="local">'Potential indications'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Early identification and support may promote safety and health for TGD youth. Intense feelings of gender dysphoria and lack of access to gender-affirming medications and caregiver support are associated with adverse long-term psychosocial and health outcomes. (See <a class="local">'Potential indications'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Spack NP, Edwards-Leeper L, Feldman HA, et al. Children and adolescents with gender identity disorder referred to a pediatric medical center. Pediatrics 2012; 129:418.</a></li><li><a class="nounderline abstract_t">de Vries AL, Cohen-Kettenis PT. Clinical management of gender dysphoria in children and adolescents: the Dutch approach. J Homosex 2012; 59:301.</a></li><li><a class="nounderline abstract_t">Hewitt JK, Paul C, Kasiannan P, et al. Hormone treatment of gender identity disorder in a cohort of children and adolescents. Med J Aust 2012; 196:578.</a></li><li><a class="nounderline abstract_t">Olson-Kennedy J, Chan YM, Rosenthal S, et al. Creating the Trans Youth Research Network: A Collaborative Research Endeavor. Transgend Health 2019; 4:304.</a></li><li><a class="nounderline abstract_t">Rafferty J, COMMITTEE ON PSYCHOSOCIAL ASPECTS OF CHILD AND FAMILY HEALTH, COMMITTEE ON ADOLESCENCE, SECTION ON LESBIAN, GAY, BISEXUAL, AND TRANSGENDER HEALTH AND WELLNESS. Ensuring Comprehensive Care and Support for Transgender and Gender-Diverse Children and Adolescents. Pediatrics 2018; 142.</a></li><li class="breakAll">University of California, San Francisco. Center of Excellence for Transgender Health. https://prevention.ucsf.edu/transhealth (Accessed on October 31, 2023).</li><li class="breakAll">Olson-Kennedy J, Rosenthal SM, Hastings J, Wesp L. Health considerations for gender non-conforming children and transgender adolescents. UCSF Center of Excellence for Transgender Health. https://prevention.ucsf.edu/transhealth (Accessed on October 31, 2023).</li><li><a class="nounderline abstract_t">Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017; 102:3869.</a></li><li><a class="nounderline abstract_t">Adelson SL, American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice parameter on gay, lesbian, or bisexual sexual orientation, gender nonconformity, and gender discordance in children and adolescents. J Am Acad Child Adolesc Psychiatry 2012; 51:957.</a></li><li class="breakAll">World Professional Association for Transgender Health (WPATH). Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Available at: https://www.tandfonline.com/doi/pdf/10.1080/26895269.2022.2100644 (Accessed on October 11, 2022).</li><li><a class="nounderline abstract_t">Olson J, Forbes C, Belzer M. Management of the transgender adolescent. Arch Pediatr Adolesc Med 2011; 165:171.</a></li><li><a class="nounderline abstract_t">Edwards-Leeper L, Spack NP. Psychological evaluation and medical treatment of transgender youth in an interdisciplinary "Gender Management Service" (GeMS) in a major pediatric center. J Homosex 2012; 59:321.</a></li><li><a class="nounderline abstract_t">Spack N. Transgenderism. Med Ethics (Burlingt Mass) 2005; 12:1.</a></li><li class="breakAll">de Vries AL, Cohen-Kettenis PT, Delemarre-Van de Waal H. Caring for transgender adolescents in BC: Suggested guidelines. Available at: transhealth.vch.ca/resources/library/tcpdocs/guidelines-adolescent.pdf (Accessed on October 05, 2012).</li><li><a class="nounderline abstract_t">Shechner T. Gender identity disorder: a literature review from a developmental perspective. Isr J Psychiatry Relat Sci 2010; 47:132.</a></li><li><a class="nounderline abstract_t">Olson KR, Durwood L, DeMeules M, McLaughlin KA. Mental Health of Transgender Children Who Are Supported in Their Identities. Pediatrics 2016; 137:e20153223.</a></li><li><a class="nounderline abstract_t">Durwood L, McLaughlin KA, Olson KR. Mental Health and Self-Worth in Socially Transitioned Transgender Youth. J Am Acad Child Adolesc Psychiatry 2017; 56:116.</a></li><li><a class="nounderline abstract_t">Olson KR, Gülgöz S. Early findings from the transyouth project: Gender development in transgender children. Child Dev Perspect 2018; 12:93.</a></li><li><a class="nounderline abstract_t">Lykens JE, LeBlanc AJ, Bockting WO. Healthcare Experiences Among Young Adults Who Identify as Genderqueer or Nonbinary. LGBT Health 2018; 5:191.</a></li><li><a class="nounderline abstract_t">Warling A, Keuroghlian AS. Clinician-Level Implications of Bans on Gender-Affirming Medical Care for Youth in the US. JAMA Pediatr 2022; 176:963.</a></li><li><a class="nounderline abstract_t">Vance SR Jr, Ehrensaft D, Rosenthal SM. Psychological and medical care of gender nonconforming youth. Pediatrics 2014; 134:1184.</a></li><li><a class="nounderline abstract_t">Hill DB, Menvielle E, Sica KM, Johnson A. An affirmative intervention for families with gender variant children: parental ratings of child mental health and gender. J Sex Marital Ther 2010; 36:6.</a></li><li><a class="nounderline abstract_t">Bonifacio JH, Maser C, Stadelman K, Palmert M. Management of gender dysphoria in adolescents in primary care. CMAJ 2019; 191:E69.</a></li><li><a class="nounderline abstract_t">Tuerk C. Considerations for affirming gender nonconforming boys and their families: new approaches, new challenges. Child Adolesc Psychiatr Clin N Am 2011; 20:767.</a></li><li><a class="nounderline abstract_t">Gender Identity Disorder in Young Boys: A parent- and peer-based treatment protocol. Clin Child Psychol Psychiatry 2002; 7:360.</a></li><li><a class="nounderline abstract_t">Rekers GA, Lovaas OI. Behavioral treatment of deviant sex-role behaviors in a male child. J Appl Behav Anal 1974; 7:173.</a></li><li><a class="nounderline abstract_t">Rekers GA, Lovaas OI, Low B. The behavioral treatment of a "transsexual" preadolescent boy. J Abnorm Child Psychol 1974; 2:99.</a></li><li class="breakAll">Substance Abuse and Mental Health Services Administration. Ending Conversion Therapy: Supporting and Affirming LGBTQ Youth. HHS Publication No. (SMA) 15-4928, Substance Abuse and Mental Health Services Administration, Rockville, MD 2015.</li><li><a class="nounderline abstract_t">Streed CG Jr, Anderson JS, Babits C, Ferguson MA. Changing Medical Practice, Not Patients - Putting an End to Conversion Therapy. N Engl J Med 2019; 381:500.</a></li><li><a class="nounderline abstract_t">Ryan C, Toomey RB, Diaz RM, Russell ST. Parent-Initiated Sexual Orientation Change Efforts With LGBT Adolescents: Implications for Young Adult Mental Health and Adjustment. J Homosex 2020; 67:159.</a></li><li><a class="nounderline abstract_t">Turban JL, Beckwith N, Reisner SL, Keuroghlian AS. Association Between Recalled Exposure to Gender Identity Conversion Efforts and Psychological Distress and Suicide Attempts Among Transgender Adults. JAMA Psychiatry 2020; 77:68.</a></li><li class="breakAll">American Academy of Child and Adolescent Psychiatry. Conversion Therapy. Available at: https://www.aacap.org/aacap/Policy_Statements/2018/Conversion_Therapy.aspx (Accessed on October 26, 2022).</li><li><a class="nounderline abstract_t">Green AE, Price-Feeney M, Dorison SH, Pick CJ. Self-Reported Conversion Efforts and Suicidality Among US LGBTQ Youths and Young Adults, 2018. Am J Public Health 2020; 110:1221.</a></li><li><a class="nounderline abstract_t">Society for Adolescent Health and Medicine. Recommendations for Promoting the Health and Well-being of Sexual and Gender-diverse Adolescents Through Supportive Families and Affirming Support Networks. J Adolesc Health 2022; 70:692.</a></li><li class="breakAll">Perrin EC. Sexual Orientation in Child and Adolescent Health Care, Springer, New York 2002.</li><li><a class="nounderline abstract_t">Kuper LE, Stewart S, Preston S, et al. Body Dissatisfaction and Mental Health Outcomes of Youth on Gender-Affirming Hormone Therapy. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Becker-Hebly I, Fahrenkrug S, Campion F, et al. Psychosocial health in adolescents and young adults with gender dysphoria before and after gender-affirming medical interventions: a descriptive study from the Hamburg Gender Identity Service. Eur Child Adolesc Psychiatry 2021; 30:1755.</a></li><li><a class="nounderline abstract_t">Achille C, Taggart T, Eaton NR, et al. Longitudinal impact of gender-affirming endocrine intervention on the mental health and well-being of transgender youths: preliminary results. Int J Pediatr Endocrinol 2020; 2020:8.</a></li><li><a class="nounderline abstract_t">Chen D, Berona J, Chan YM, et al. Psychosocial Functioning in Transgender Youth after 2 Years of Hormones. N Engl J Med 2023; 388:240.</a></li><li><a class="nounderline abstract_t">Gibson DJ, Glazier JJ, Olson KR. Evaluation of Anxiety and Depression in a Community Sample of Transgender Youth. JAMA Netw Open 2021; 4:e214739.</a></li><li><a class="nounderline abstract_t">Coates S, Person ES. Extreme boyhood femininity: isolated behavior or pervasive disorder? J Am Acad Child Psychiatry 1985; 24:702.</a></li><li><a class="nounderline abstract_t">Rosen AC, Rekers GA, Friar LR. Theoretical and Diagnostic Issues in Child Gender Disturbances. J Sex Res 1977; 13:89.</a></li><li><a class="nounderline abstract_t">Yunger JL, Carver PR, Perry DG. Does gender identity influence children's psychological well-being? Dev Psychol 2004; 40:572.</a></li><li><a class="nounderline abstract_t">Zucker KJ. Gender identity disorder in children and adolescents. Annu Rev Clin Psychol 2005; 1:467.</a></li><li><a class="nounderline abstract_t">Lavender R, Shaw S, Maninger JK, et al. Impact of Hormone Treatment on Psychosocial Functioning in Gender-Diverse Young People. LGBT Health 2023; 10:382.</a></li><li><a class="nounderline abstract_t">Olson-Kennedy J, Warus J, Okonta V, et al. Chest Reconstruction and Chest Dysphoria in Transmasculine Minors and Young Adults: Comparisons of Nonsurgical and Postsurgical Cohorts. JAMA Pediatr 2018; 172:431.</a></li><li><a class="nounderline abstract_t">Steensma TD, van der Ende J, Verhulst FC, Cohen-Kettenis PT. Gender variance in childhood and sexual orientation in adulthood: a prospective study. J Sex Med 2013; 10:2723.</a></li><li><a class="nounderline abstract_t">Zucker KJ. On the "natural history" of gender identity disorder in children. J Am Acad Child Adolesc Psychiatry 2008; 47:1361.</a></li><li><a class="nounderline abstract_t">Drescher J, Byne W. Gender dysphoric/gender variant (GD/GV) children and adolescents: summarizing what we know and what we have yet to learn. J Homosex 2012; 59:501.</a></li><li><a class="nounderline abstract_t">Reilly M, Desousa V, Garza-Flores A, Perrin EC. Young Children With Gender Nonconforming Behaviors and Preferences. J Dev Behav Pediatr 2019; 40:60.</a></li><li><a class="nounderline abstract_t">Katz-Wise SL, Gordon AR, Sharp KJ, et al. Developing Parenting Guidelines to Support Transgender and Gender Diverse Children's Well-being. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Steensma TD, McGuire JK, Kreukels BP, et al. Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study. J Am Acad Child Adolesc Psychiatry 2013; 52:582.</a></li><li><a class="nounderline abstract_t">Simons L, Schrager SM, Clark LF, et al. Parental support and mental health among transgender adolescents. J Adolesc Health 2013; 53:791.</a></li><li><a class="nounderline abstract_t">Olson KR, Durwood L, Horton R, et al. Gender Identity 5 Years After Social Transition. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Steensma TD, Biemond R, de Boer F, Cohen-Kettenis PT. Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study. Clin Child Psychol Psychiatry 2011; 16:499.</a></li><li><a class="nounderline abstract_t">Rankine J, Kidd KM, Sequeira GM, et al. Adolescent Perspectives on the Use of Telemedicine for Confidential Health Care: An Exploratory Mixed-Methods Study. J Adolesc Health 2023; 73:360.</a></li><li><a class="nounderline abstract_t">Cocchetti C, Ristori J, Romani A, et al. Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals. J Clin Med 2020; 9.</a></li><li><a class="nounderline abstract_t">Xu JY, O'Connell MA, Notini L, et al. Selective Estrogen Receptor Modulators: A Potential Option For Non-Binary Gender-Affirming Hormonal Care? Front Endocrinol (Lausanne) 2021; 12:701364.</a></li><li><a class="nounderline abstract_t">Pang KC, Notini L, McDougall R, et al. Long-term Puberty Suppression for a Nonbinary Teenager. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Liszewski W, Peebles JK, Yeung H, Arron S. Persons of Nonbinary Gender - Awareness, Visibility, and Health Disparities. N Engl J Med 2018; 379:2391.</a></li><li><a class="nounderline abstract_t">Vrouenraets LJJJ, de Vries ALC, de Vries MC, et al. Assessing Medical Decision-Making Competence in Transgender Youth. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Dunn LB, Nowrangi MA, Palmer BW, et al. Assessing decisional capacity for clinical research or treatment: a review of instruments. Am J Psychiatry 2006; 163:1323.</a></li><li><a class="nounderline abstract_t">Committee Opinion No. 685: Care for Transgender Adolescents. Obstet Gynecol 2017; 129:e11.</a></li><li><a class="nounderline abstract_t">Light AD, Obedin-Maliver J, Sevelius JM, Kerns JL. Transgender men who experienced pregnancy after female-to-male gender transitioning. Obstet Gynecol 2014; 124:1120.</a></li><li><a class="nounderline abstract_t">Johnson EK, Finlayson C. Preservation of Fertility Potential for Gender and Sex Diverse Individuals. Transgend Health 2016; 1:41.</a></li><li><a class="nounderline abstract_t">Martin CE, Lewis C, Omurtag K. Successful oocyte cryopreservation using letrozole as an adjunct to stimulation in a transgender adolescent after GnRH agonist suppression. Fertil Steril 2021; 116:522.</a></li><li><a class="nounderline abstract_t">Insogna IG, Ginsburg E, Srouji S. Fertility Preservation for Adolescent Transgender Male Patients: A Case Series. J Adolesc Health 2020; 66:750.</a></li><li><a class="nounderline abstract_t">Obedin-Maliver J, Makadon HJ. Transgender men and pregnancy. Obstet Med 2016; 9:4.</a></li><li><a class="nounderline abstract_t">Chen D, Simons L, Johnson EK, et al. Fertility Preservation for Transgender Adolescents. J Adolesc Health 2017; 61:120.</a></li><li><a class="nounderline abstract_t">Finlayson C, Johnson EK, Chen D, et al. Proceedings of the Working Group Session on Fertility Preservation for Individuals with Gender and Sex Diversity. Transgend Health 2016; 1:99.</a></li><li><a class="nounderline abstract_t">Wallace SA, Blough KL, Kondapalli LA. Fertility preservation in the transgender patient: expanding oncofertility care beyond cancer. Gynecol Endocrinol 2014; 30:868.</a></li><li><a class="nounderline abstract_t">Nahata L, Chen D, Moravek MB, et al. Understudied and Under-Reported: Fertility Issues in Transgender Youth-A Narrative Review. J Pediatr 2019; 205:265.</a></li><li><a class="nounderline abstract_t">Chen D, Matson M, Macapagal K, et al. Attitudes Toward Fertility and Reproductive Health Among Transgender and Gender-Nonconforming Adolescents. J Adolesc Health 2018; 63:62.</a></li><li><a class="nounderline abstract_t">Persky RW, Gruschow SM, Sinaii N, et al. Attitudes Toward Fertility Preservation Among Transgender Youth and Their Parents. J Adolesc Health 2020; 67:583.</a></li><li><a class="nounderline abstract_t">Halloran J, Smidt AM, Morrison A, et al. Reproductive and fertility knowledge and attitudes among transgender and gender-expansive youth: a replication and extension. Transgend Health 2022.</a></li><li><a class="nounderline abstract_t">Gridley SJ, Crouch JM, Evans Y, et al. Youth and Caregiver Perspectives on Barriers to Gender-Affirming Health Care for Transgender Youth. J Adolesc Health 2016; 59:254.</a></li><li><a class="nounderline abstract_t">Weixel T, Wildman B. Geographic Distribution of Clinical Care for Transgender and Gender-Diverse Youth. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Stevens J, Gomez-Lobo V, Pine-Twaddell E. Insurance Coverage of Puberty Blocker Therapies for Transgender Youth. Pediatrics 2015; 136:1029.</a></li><li><a class="nounderline abstract_t">Klein DA, Roberts TA, Adirim TA, et al. Transgender Children and Adolescents Receiving Care in the US Military Health Care System. JAMA Pediatr 2019; 173:491.</a></li><li><a class="nounderline abstract_t">Garofalo R, Deleon J, Osmer E, et al. Overlooked, misunderstood and at-risk: exploring the lives and HIV risk of ethnic minority male-to-female transgender youth. J Adolesc Health 2006; 38:230.</a></li><li><a class="nounderline abstract_t">Rotondi NK, Bauer GR, Scanlon K, et al. Nonprescribed hormone use and self-performed surgeries: "do-it-yourself" transitions in transgender communities in Ontario, Canada. Am J Public Health 2013; 103:1830.</a></li><li class="breakAll">Watts J, Graham C. Primary care. In: Pediatric gender identity: Gender-affirming care for transgender and gender-diverse youth, Forcier M, VanSchalkwyk G, Turban JL (Eds), pringer Nature Switzerland, 2020. p.111.</li><li><a class="nounderline abstract_t">Zucker KJ. The DSM diagnostic criteria for gender identity disorder in children. Arch Sex Behav 2010; 39:477.</a></li><li><a class="nounderline abstract_t">Brik T, Vrouenraets LJJJ, de Vries MC, Hannema SE. Trajectories of Adolescents Treated with Gonadotropin-Releasing Hormone Analogues for Gender Dysphoria. Arch Sex Behav 2020; 49:2611.</a></li><li><a class="nounderline abstract_t">Wiepjes CM, Nota NM, de Blok CJM, et al. The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): Trends in Prevalence, Treatment, and Regrets. J Sex Med 2018; 15:582.</a></li><li><a class="nounderline abstract_t">van der Loos MATC, Hannema SE, Klink DT, et al. Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands. Lancet Child Adolesc Health 2022; 6:869.</a></li><li><a class="nounderline abstract_t">Cohen-Kettenis PT, van Goozen SH. Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent. Eur Child Adolesc Psychiatry 1998; 7:246.</a></li><li><a class="nounderline abstract_t">Delemarre-van de Waal, Cohen-Kettenis PT. Clinical management of gender identity disorder in adolescents: A protocol on psychological and paediatric endocrinology aspects. Eur J Endocrinol 2006; 155 Suppl 1:S131.</a></li><li><a class="nounderline abstract_t">Malpas J. Between pink and blue: a multi-dimensional family approach to gender nonconforming children and their families. Fam Process 2011; 50:453.</a></li><li><a class="nounderline abstract_t">Manasco PK, Pescovitz OH, Feuillan PP, et al. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab 1988; 67:368.</a></li><li><a class="nounderline abstract_t">Khatchadourian K, Amed S, Metzger DL. Clinical management of youth with gender dysphoria in Vancouver. J Pediatr 2014; 164:906.</a></li><li><a class="nounderline abstract_t">Jensen RK, Jensen JK, Simons LK, et al. Effect of Concurrent Gonadotropin-Releasing Hormone Agonist Treatment on Dose and Side Effects of Gender-Affirming Hormone Therapy in Adolescent Transgender Patients. Transgend Health 2019; 4:300.</a></li><li><a class="nounderline abstract_t">van de Grift TC, van Gelder ZJ, Mullender MG, et al. Timing of Puberty Suppression and Surgical Options for Transgender Youth. Pediatrics 2020; 146.</a></li><li><a class="nounderline abstract_t">Vrouenraets LJJJ, de Vries MC, Hein IM, et al. Perceptions on the function of puberty suppression of transgender adolescents who continued or discontinued treatment, their parents, and clinicians. Int J Transgend Health 2022; 23:428.</a></li><li><a class="nounderline abstract_t">Chew D, Anderson J, Williams K, et al. Hormonal Treatment in Young People With Gender Dysphoria: A Systematic Review. Pediatrics 2018; 141.</a></li><li><a class="nounderline abstract_t">Tordoff DM, Wanta JW, Collin A, et al. Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care. JAMA Netw Open 2022; 5:e220978.</a></li><li><a class="nounderline abstract_t">van der Miesen AIR, Steensma TD, de Vries ALC, et al. Psychological Functioning in Transgender Adolescents Before and After Gender-Affirmative Care Compared With Cisgender General Population Peers. J Adolesc Health 2020; 66:699.</a></li><li><a class="nounderline abstract_t">Costa R, Dunsford M, Skagerberg E, et al. Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria. J Sex Med 2015; 12:2206.</a></li><li><a class="nounderline abstract_t">de Vries AL, Steensma TD, Doreleijers TA, Cohen-Kettenis PT. Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. J Sex Med 2011; 8:2276.</a></li><li><a class="nounderline abstract_t">de Vries AL, McGuire JK, Steensma TD, et al. Young adult psychological outcome after puberty suppression and gender reassignment. Pediatrics 2014; 134:696.</a></li><li><a class="nounderline abstract_t">Turban JL, King D, Carswell JM, Keuroghlian AS. Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Akgul S, Bonny AE, Ford N, et al. Experiences of Gender Minority Youth With the Intrauterine System. J Adolesc Health 2019; 65:32.</a></li><li><a class="nounderline abstract_t">Menvielle E, Gomez-Lobo V. Management of children and adolescents with gender dysphoria. J Pediatr Adolesc Gynecol 2011; 24:183.</a></li><li><a class="nounderline abstract_t">Meyer WJ 3rd. Gender identity disorder: an emerging problem for pediatricians. Pediatrics 2012; 129:571.</a></li><li><a class="nounderline abstract_t">Jain J, Dutton C, Nicosia A, et al. Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera. Contraception 2004; 70:11.</a></li><li><a class="nounderline abstract_t">Mieszczak J, Eugster EA. Treatment of precocious puberty in McCune-Albright syndrome. Pediatr Endocrinol Rev 2007; 4 Suppl 4:419.</a></li><li><a class="nounderline abstract_t">Richman RA, Underwood LE, French FS, Van Wyk JJ. Adverse effects of large doses of medroxyprogesterone (MPA) in idiopathic isosexual precocity. J Pediatr 1971; 79:963.</a></li><li class="breakAll">Australasian Paediatric Endocrine Group. Gender Identity Disorder Guidelines. http://www.apeg.org.au/Portals/0/guidelines.pdf (Accessed on October 08, 2012).</li><li><a class="nounderline abstract_t">Pine-Twaddell E, Newfield RS, Marinkovic M. Extended Use of Histrelin Implant in Pediatric Patients. Transgend Health 2023; 8:264.</a></li><li><a class="nounderline abstract_t">Ciancia S, Klink D, Craen M, Cools M. Early puberty suppression and gender-affirming hormones do not alter final height in transgender adolescents. Eur J Endocrinol 2023; 189:396.</a></li><li><a class="nounderline abstract_t">van der Loos MATC, Vlot MC, Klink DT, et al. Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones. JAMA Pediatr 2023; 177:1332.</a></li><li><a class="nounderline abstract_t">Lee JY, Finlayson C, Olson-Kennedy J, et al. Low Bone Mineral Density in Early Pubertal Transgender/Gender Diverse Youth: Findings From the Trans Youth Care Study. J Endocr Soc 2020; 4:bvaa065.</a></li><li><a class="nounderline abstract_t">Navabi B, Tang K, Khatchadourian K, Lawson ML. Pubertal Suppression, Bone Mass, and Body Composition in Youth With Gender Dysphoria. Pediatrics 2021; 148.</a></li><li><a class="nounderline abstract_t">Hodax JK, Brady C, DiVall S, et al. Low Pretreatment Bone Mineral Density in Gender Diverse Youth. Transgend Health 2023; 8:467.</a></li><li><a class="nounderline abstract_t">Cohen-Kettenis PT, Schagen SE, Steensma TD, et al. Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up. Arch Sex Behav 2011; 40:843.</a></li><li><a class="nounderline abstract_t">Vlot MC, Klink DT, den Heijer M, et al. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents. Bone 2017; 95:11.</a></li><li><a class="nounderline abstract_t">Schagen SEE, Wouters FM, Cohen-Kettenis PT, et al. Bone Development in Transgender Adolescents Treated With GnRH Analogues and Subsequent Gender-Affirming Hormones. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Kiesel LA, Rody A, Greb RR, Szilágyi A. Clinical use of GnRH analogues. Clin Endocrinol (Oxf) 2002; 56:677.</a></li><li><a class="nounderline abstract_t">Green AE, DeChants JP, Price MN, Davis CK. Association of Gender-Affirming Hormone Therapy With Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth. J Adolesc Health 2022; 70:643.</a></li><li><a class="nounderline abstract_t">Olsavsky AL, Grannis C, Bricker J, et al. Associations Among Gender-Affirming Hormonal Interventions, Social Support, and Transgender Adolescents' Mental Health. J Adolesc Health 2023; 72:860.</a></li><li><a class="nounderline abstract_t">Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348:977.</a></li><li><a class="nounderline abstract_t">Gerstman BB, Piper JM, Tomita DK, et al. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991; 133:32.</a></li><li><a class="nounderline abstract_t">Mullins ES, Geer R, Metcalf M, et al. Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy. Pediatrics 2021; 147.</a></li><li><a class="nounderline abstract_t">Richman RA, Kirsch LR. Testosterone treatment in adolescent boys with constitutional delay in growth and development. N Engl J Med 1988; 319:1563.</a></li><li><a class="nounderline abstract_t">Jones SC. Subcutaneous estrogen replacement therapy. J Reprod Med 2004; 49:139.</a></li><li><a class="nounderline abstract_t">Toorians AW, Thomassen MC, Zweegman S, et al. Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people. J Clin Endocrinol Metab 2003; 88:5723.</a></li><li><a class="nounderline abstract_t">Hannema SE, Schagen SEE, Cohen-Kettenis PT, Delemarre-van de Waal HA. The efficacy and safety of pubertal induction using 17beta-estradiol in transgirls. J Clin Endocrinol Metab 2017.</a></li><li><a class="nounderline abstract_t">Jarin J, Pine-Twaddell E, Trotman G, et al. Cross-Sex Hormones and Metabolic Parameters in Adolescents With Gender Dysphoria. Pediatrics 2017; 139.</a></li><li><a class="nounderline abstract_t">Klaver M, de Mutsert R, van der Loos MATC, et al. Hormonal Treatment and Cardiovascular Risk Profile in Transgender Adolescents. Pediatrics 2020; 145.</a></li><li><a class="nounderline abstract_t">Valentine A, Davis S, Furniss A, et al. Multicenter Analysis of Cardiometabolic-related Diagnoses in Transgender and Gender-Diverse Youth: A PEDSnet Study. J Clin Endocrinol Metab 2022; 107:e4004.</a></li><li><a class="nounderline abstract_t">Laurenzano SE, Newfield RS, Lee E, Marinkovic M. Subcutaneous Testosterone Is Effective and Safe as Gender-Affirming Hormone Therapy in Transmasculine and Gender-Diverse Adolescents and Young Adults: A Single Center's 8-Year Experience. Transgend Health 2021; 6:343.</a></li><li><a class="nounderline abstract_t">Olson-Kennedy J, Okonta V, Clark LF, Belzer M. Physiologic Response to Gender-Affirming Hormones Among Transgender Youth. J Adolesc Health 2018; 62:397.</a></li><li><a class="nounderline abstract_t">Pham A, Camfield C, Curtis A, et al. A Mixed Methods Study on Healthcare Transition From Pediatric to Adult Care in Transgender and Gender-Diverse Adolescents and Young Adults. J Adolesc Health 2023; 73:375.</a></li></ol></div><div id="topicVersionRevision">Topic 86771 Version 58.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22351896" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Children and adolescents with gender identity disorder referred to a pediatric medical center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22455322" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical management of gender dysphoria in children and adolescents: the Dutch approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22621149" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hormone treatment of gender identity disorder in a cohort of children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31701011" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Creating the Trans Youth Research Network: A Collaborative Research Endeavor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30224363" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Ensuring Comprehensive Care and Support for Transgender and Gender-Diverse Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30224363" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Ensuring Comprehensive Care and Support for Transgender and Gender-Diverse Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30224363" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ensuring Comprehensive Care and Support for Transgender and Gender-Diverse Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28945902" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22917211" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Practice parameter on gay, lesbian, or bisexual sexual orientation, gender nonconformity, and gender discordance in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22917211" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Practice parameter on gay, lesbian, or bisexual sexual orientation, gender nonconformity, and gender discordance in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21300658" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Management of the transgender adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22455323" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Psychological evaluation and medical treatment of transgender youth in an interdisciplinary "Gender Management Service" (GeMS) in a major pediatric center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16358482" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Transgenderism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16358482" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transgenderism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20733256" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Gender identity disorder: a literature review from a developmental perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26921285" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mental Health of Transgender Children Who Are Supported in Their Identities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28117057" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Mental Health and Self-Worth in Socially Transitioned Transgender Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Early findings from the transyouth project: Gender development in transgender children</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29641314" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Healthcare Experiences Among Young Adults Who Identify as Genderqueer or Nonbinary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35939318" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinician-Level Implications of Bans on Gender-Affirming Medical Care for Youth in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25404716" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Psychological and medical care of gender nonconforming youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20063232" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : An affirmative intervention for families with gender variant children: parental ratings of child mental health and gender.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30665976" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Management of gender dysphoria in adolescents in primary care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22051012" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Considerations for affirming gender nonconforming boys and their families: new approaches, new challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Gender Identity Disorder in Young Boys: A parent- and peer-based treatment protocol</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4436165" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Behavioral treatment of deviant sex-role behaviors in a male child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4430820" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : The behavioral treatment of a "transsexual" preadolescent boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4430820" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The behavioral treatment of a "transsexual" preadolescent boy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31390498" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Changing Medical Practice, Not Patients - Putting an End to Conversion Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30403564" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Parent-Initiated Sexual Orientation Change Efforts With LGBT Adolescents: Implications for Young Adult Mental Health and Adjustment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31509158" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Association Between Recalled Exposure to Gender Identity Conversion Efforts and Psychological Distress and Suicide Attempts Among Transgender Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31509158" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Association Between Recalled Exposure to Gender Identity Conversion Efforts and Psychological Distress and Suicide Attempts Among Transgender Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32552019" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Self-Reported Conversion Efforts and Suicidality Among US LGBTQ Youths and Young Adults, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35181244" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Recommendations for Promoting the Health and Well-being of Sexual and Gender-diverse Adolescents Through Supportive Families and Affirming Support Networks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35181244" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Recommendations for Promoting the Health and Well-being of Sexual and Gender-diverse Adolescents Through Supportive Families and Affirming Support Networks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32220906" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Body Dissatisfaction and Mental Health Outcomes of Youth on Gender-Affirming Hormone Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32990772" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Psychosocial health in adolescents and young adults with gender dysphoria before and after gender-affirming medical interventions: a descriptive study from the Hamburg Gender Identity Service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32368216" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Longitudinal impact of gender-affirming endocrine intervention on the mental health and well-being of transgender youths: preliminary results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36652355" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Psychosocial Functioning in Transgender Youth after 2 Years of Hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33825842" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Evaluation of Anxiety and Depression in a Community Sample of Transgender Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4067139" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Extreme boyhood femininity: isolated behavior or pervasive disorder?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Theoretical and Diagnostic Issues in Child Gender Disturbances</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15238044" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Does gender identity influence children's psychological well-being?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17716096" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Gender identity disorder in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36989498" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Impact of Hormone Treatment on Psychosocial Functioning in Gender-Diverse Young People.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29507933" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Chest Reconstruction and Chest Dysphoria in Transmasculine Minors and Young Adults: Comparisons of Nonsurgical and Postsurgical Cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22458332" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gender variance in childhood and sexual orientation in adulthood: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19034186" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : On the "natural history" of gender identity disorder in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22455333" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Gender dysphoric/gender variant (GD/GV) children and adolescents: summarizing what we know and what we have yet to learn.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30247388" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Young Children With Gender Nonconforming Behaviors and Preferences.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36045300" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Developing Parenting Guidelines to Support Transgender and Gender Diverse Children's Well-being.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23702447" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Factors associated with desistence and persistence of childhood gender dysphoria: a quantitative follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24012067" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Parental support and mental health among transgender adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35505568" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Gender Identity 5 Years After Social Transition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21216800" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Desisting and persisting gender dysphoria after childhood: a qualitative follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37227338" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Adolescent Perspectives on the Use of Telemedicine for Confidential Health Care: An Exploratory Mixed-Methods Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32466485" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34226826" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Selective Estrogen Receptor Modulators: A Potential Option For Non-Binary Gender-Affirming Hormonal Care?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31974217" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Long-term Puberty Suppression for a Nonbinary Teenager.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30575476" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Persons of Nonbinary Gender - Awareness, Visibility, and Health Disparities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34850191" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Assessing Medical Decision-Making Competence in Transgender Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16877642" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Assessing decisional capacity for clinical research or treatment: a review of instruments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28002311" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Committee Opinion No. 685: Care for Transgender Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25415163" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Transgender men who experienced pregnancy after female-to-male gender transitioning.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29159296" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Preservation of Fertility Potential for Gender and Sex Diverse Individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33795140" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Successful oocyte cryopreservation using letrozole as an adjunct to stimulation in a transgender adolescent after GnRH agonist suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32001141" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Fertility Preservation for Adolescent Transgender Male Patients: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27030799" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Transgender men and pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28363716" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Fertility Preservation for Transgender Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28111635" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Proceedings of the Working Group Session on Fertility Preservation for Individuals with Gender and Sex Diversity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25254620" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Fertility preservation in the transgender patient: expanding oncofertility care beyond cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30293639" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Understudied and Under-Reported: Fertility Issues in Transgender Youth-A Narrative Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29503031" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Attitudes Toward Fertility and Reproductive Health Among Transgender and Gender-Nonconforming Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32359942" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Attitudes Toward Fertility Preservation Among Transgender Youth and Their Parents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Reproductive and fertility knowledge and attitudes among transgender and gender-expansive youth: a replication and extension</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27235374" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Youth and Caregiver Perspectives on Barriers to Gender-Affirming Health Care for Transgender Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36443242" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Geographic Distribution of Clinical Care for Transgender and Gender-Diverse Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26527547" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Insurance Coverage of Puberty Blocker Therapies for Transgender Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30907932" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Transgender Children and Adolescents Receiving Care in the US Military Health Care System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488820" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Overlooked, misunderstood and at-risk: exploring the lives and HIV risk of ethnic minority male-to-female transgender youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23948009" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Nonprescribed hormone use and self-performed surgeries: "do-it-yourself" transitions in transgender communities in Ontario, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23948009" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Nonprescribed hormone use and self-performed surgeries: "do-it-yourself" transitions in transgender communities in Ontario, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19842027" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The DSM diagnostic criteria for gender identity disorder in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32152785" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Trajectories of Adolescents Treated with Gonadotropin-Releasing Hormone Analogues for Gender Dysphoria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29463477" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The Amsterdam Cohort of Gender Dysphoria Study (1972-2015): Trends in Prevalence, Treatment, and Regrets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36273487" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9879847" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Clinical management of gender identity disorder in adolescents: A protocol on psychological and paediatric endocrinology aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22145719" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Between pink and blue: a multi-dimensional family approach to gender nonconforming children and their families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3292562" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24315505" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Clinical management of youth with gender dysphoria in Vancouver.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31663037" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Effect of Concurrent Gonadotropin-Releasing Hormone Agonist Treatment on Dose and Side Effects of Gender-Affirming Hormone Therapy in Adolescent Transgender Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33106340" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Timing of Puberty Suppression and Surgical Options for Transgender Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36324881" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Perceptions on the function of puberty suppression of transgender adolescents who continued or discontinued treatment, their parents, and clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29514975" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Hormonal Treatment in Young People With Gender Dysphoria: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35212746" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32273193" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Psychological Functioning in Transgender Adolescents Before and After Gender-Affirmative Care Compared With Cisgender General Population Peers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26556015" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Psychological Support, Puberty Suppression, and Psychosocial Functioning in Adolescents with Gender Dysphoria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20646177" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25201798" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Young adult psychological outcome after puberty suppression and gender reassignment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31974216" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pubertal Suppression for Transgender Youth and Risk of Suicidal Ideation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30691940" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Experiences of Gender Minority Youth With the Intrauterine System.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21600803" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Management of children and adolescents with gender dysphoria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22351880" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Gender identity disorder: an emerging problem for pediatricians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15208047" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17982389" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Treatment of precocious puberty in McCune-Albright syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4332067" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Adverse effects of large doses of medroxyprogesterone (MPA) in idiopathic isosexual precocity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4332067" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Adverse effects of large doses of medroxyprogesterone (MPA) in idiopathic isosexual precocity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37342480" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Extended Use of Histrelin Implant in Pediatric Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37703317" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Early puberty suppression and gender-affirming hormones do not alter final height in transgender adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37902760" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32832823" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Low Bone Mineral Density in Early Pubertal Transgender/Gender Diverse Youth: Findings From the Trans Youth Care Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34497118" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Pubertal Suppression, Bone Mass, and Body Composition in Youth With Gender Dysphoria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37810939" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Low Pretreatment Bone Mineral Density in Gender Diverse Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21503817" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Puberty suppression in a gender-dysphoric adolescent: a 22-year follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27845262" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32909025" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Bone Development in Transgender Adolescents Treated With GnRH Analogues and Subsequent Gender-Affirming Hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12072036" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Clinical use of GnRH analogues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34920935" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Association of Gender-Affirming Hormone Therapy With Depression, Thoughts of Suicide, and Attempted Suicide Among Transgender and Nonbinary Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37029048" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Associations Among Gender-Affirming Hormonal Interventions, Social Support, and Transgender Adolescents' Mental Health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8855852" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Risk of venous thromboembolism in users of hormone replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1983896" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33753543" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3200264" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Testosterone treatment in adolescent boys with constitutional delay in growth and development.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15098881" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Subcutaneous estrogen replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14671159" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28419243" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : The efficacy and safety of pubertal induction using 17beta-estradiol in transgirls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28557738" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Cross-Sex Hormones and Metabolic Parameters in Adolescents With Gender Dysphoria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32102929" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Hormonal Treatment and Cardiovascular Risk Profile in Transgender Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35945152" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Multicenter Analysis of Cardiometabolic-related Diagnoses in Transgender and Gender-Diverse Youth: A PEDSnet Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34988290" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Subcutaneous Testosterone Is Effective and Safe as Gender-Affirming Hormone Therapy in Transmasculine and Gender-Diverse Adolescents and Young Adults: A Single Center's 8-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29056436" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Physiologic Response to Gender-Affirming Hormones Among Transgender Youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37294254" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : A Mixed Methods Study on Healthcare Transition From Pediatric to Adult Care in Transgender and Gender-Diverse Adolescents and Young Adults.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
